Trial Outcomes & Findings for Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.) (NCT NCT04982445)
NCT ID: NCT04982445
Last Updated: 2025-04-01
Results Overview
Feasibility of Intervention Measure (FIM) were employed to evaluate the feasibility of CABENUVA administration at Infusion Centers (IC)/ alternate sites of administration (ASA). Higher scores on FIM indicate greater feasibility, where each item can be scored from 1 to 5: Completely disagree (score=1), disagree (score=2), neither agree or disagree (score=3), agree (score=4), completely agree (score=5). This scoring looked at the number responding '4' or '5' to each question divided by the number completing all 4-items where "items" refer to the individual questions or statements that participants respond to in order to assess their perceptions of an intervention. Each item is designed to measure a specific aspect of either acceptability or feasibility.
Recruitment status
COMPLETED
Study phase
PHASE4
Target enrollment
44 participants
Primary outcome timeframe
At Month 8
Results posted on
2025-04-01
Participant Flow
A total of 44 patients living with HIV (PLWHIV) were enrolled in the study and all of them received study treatment and were included in the safety population. Staff such as HIV care providers and IC/ ASA staff were not counted as enrolled.
Participant milestones
| Measure |
Participants Receiving CABENUVA
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Overall Study
STARTED
|
44
|
|
Overall Study
COMPLETED
|
38
|
|
Overall Study
NOT COMPLETED
|
6
|
Reasons for withdrawal
| Measure |
Participants Receiving CABENUVA
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Overall Study
Protocol Violation
|
1
|
|
Overall Study
Withdrawal by Subject
|
4
|
|
Overall Study
Lost to Follow-up
|
1
|
Baseline Characteristics
Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)
Baseline characteristics by cohort
| Measure |
Participants Receiving CABENUVA
n=44 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Age, Continuous
|
46.8 Years
STANDARD_DEVIATION 12.64 • n=99 Participants
|
|
Sex/Gender, Customized
Male
|
35 Participants
n=99 Participants
|
|
Sex/Gender, Customized
Female
|
9 Participants
n=99 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
3 Participants
n=99 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
41 Participants
n=99 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
PRIMARY outcome
Timeframe: At Month 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Feasibility of Intervention Measure (FIM) were employed to evaluate the feasibility of CABENUVA administration at Infusion Centers (IC)/ alternate sites of administration (ASA). Higher scores on FIM indicate greater feasibility, where each item can be scored from 1 to 5: Completely disagree (score=1), disagree (score=2), neither agree or disagree (score=3), agree (score=4), completely agree (score=5). This scoring looked at the number responding '4' or '5' to each question divided by the number completing all 4-items where "items" refer to the individual questions or statements that participants respond to in order to assess their perceptions of an intervention. Each item is designed to measure a specific aspect of either acceptability or feasibility.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=37 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the Feasibility of Intervention Measure (FIM)
|
31 Participants
|
SECONDARY outcome
Timeframe: At Months 1 and 3Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=43 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM at Month 1 and 3
Month 1
|
37 Participants
|
|
Number of Participants Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM at Month 1 and 3
Month 3
|
31 Participants
|
SECONDARY outcome
Timeframe: At Months 1, 4, and 8Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=3 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of HIV Care Providers Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM at Month 1, 4 and 8
Month 1
|
1 Participants
|
|
Number of HIV Care Providers Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM at Month 1, 4 and 8
Month 4
|
1 Participants
|
|
Number of HIV Care Providers Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM at Month 1, 4 and 8
Month 8
|
0 Participants
|
SECONDARY outcome
Timeframe: Prior to Month 1 (Baseline) and at Months 3 and 8Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=113 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of IC/ ASA Staff Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM Prior to Month 1 and at Months 3 and 8
Prior to Month 1 (Baseline)
|
50 Participants
|
|
Number of IC/ ASA Staff Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM Prior to Month 1 and at Months 3 and 8
Month 3
|
19 Participants
|
|
Number of IC/ ASA Staff Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM Prior to Month 1 and at Months 3 and 8
Month 8
|
11 Participants
|
SECONDARY outcome
Timeframe: From Month 1 (Baseline) to Months 3 and 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
The mean score for feasibility of the intervention administration was calculated by averaging the responses from the 4 items. The responses were scored based on a scale of 1 to 5 where 1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=36 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Change in FIM Score Over Time in Participants at Month 3 and 8
From Baseline to Month 3
|
0.06 Scores on a scale
Standard Deviation 0.667
|
|
Change in FIM Score Over Time in Participants at Month 3 and 8
From Baseline to Month 8
|
-0.03 Scores on a scale
Standard Deviation 0.677
|
SECONDARY outcome
Timeframe: From Month 1 (Baseline) to Months 4 and 8Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=3 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Change in FIM Score Over Time in HIV Care Providers at Month 4 and 8
From Baseline to Month 4
|
0.33 Scores on a scale
Standard Deviation 0.764
|
|
Change in FIM Score Over Time in HIV Care Providers at Month 4 and 8
From Baseline to Month 8
|
0.38 Scores on a scale
Standard Deviation 0.177
|
SECONDARY outcome
Timeframe: From Month 1 (Baseline) to Months 3 and 8Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=34 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Change in FIM Score Over Time in IC/ ASA Staff at Month 3 and 8
From Baseline to Month 3
|
-0.04 Scores on a scale
Standard Deviation 0.729
|
|
Change in FIM Score Over Time in IC/ ASA Staff at Month 3 and 8
From Baseline to Month 8
|
-0.20 Scores on a scale
Standard Deviation 0.700
|
SECONDARY outcome
Timeframe: At Month 1Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
The tailored questionnaire for participants receiving CABENUVA was developed specifically for this study and contains items regarding the reasons for switching to CABENUVA, adherence to their previous oral HIV medication, preferences and attitudes regarding their medication regimen, and perceived advantages and disadvantages of receiving injections at the IC/ASA. In this outcome measure, participants were asked about their views on the IC/ASA administration model (any/biggest concerns about receiving CABENUVA at an infusion center).
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=44 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1
Forgetting my appointments for the CABENUVA visits
|
6 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1
No current worries about receiving CABENUVA at an infusion center
|
19 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1
Scheduling upcoming CABENUVA visits
|
7 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1
My doctor not knowing if I have a bad reaction
|
4 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1
Other
|
4 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1
The infusion center managing my pain or soreness from CABENUVA
|
3 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1
The infusion center managing the side effects from CABENUVA
|
3 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1
The infusion center not aware of my other medical history
|
3 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1
Transportation to the infusion center for the CABENUVA visits
|
3 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1
The infusion center hours for CABENUVA visits
|
3 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1
Others at the clinic may find out that I am HIV positive
|
3 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1
Frequency of the required visits to the infusion center clinic as well as my primary HIV doctor
|
2 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1
Rescheduling missed CABENUVA visits
|
1 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1
Infusion center not aware of my other medications and possible interactions
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1
Parking at the infusion center for CABENUVA visits
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1
Childcare during CABENUVA visits
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1
Infusion center not being an HIV-specific clinic
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 1
Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: At Month 3 and 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
The tailored questionnaire for participants receiving CABENUVA was developed specifically for this study and contains items regarding the reasons for switching to CABENUVA, adherence to their previous oral HIV medication, preferences and attitudes regarding their medication regimen, and perceived advantages and disadvantages of receiving injections at the IC/ASA. In this outcome measure, participants were asked about their views on the IC/ASA administration model (any concerns about continuing to receive CABENUVA at an infusion center) at Months 3 and 8.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=41 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration (Concern About Continuing to Receive CABENUVA) by Other Quantitative Questionnaires at Month 3 and 8
Month 3- Do you have any concerns about continuing to receive CABENUVA at an infusion center? · Yes
|
3 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration (Concern About Continuing to Receive CABENUVA) by Other Quantitative Questionnaires at Month 3 and 8
Month 3- Do you have any concerns about continuing to receive CABENUVA at an infusion center? · No
|
33 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration (Concern About Continuing to Receive CABENUVA) by Other Quantitative Questionnaires at Month 3 and 8
Month 3- Do you have any concerns about continuing to receive CABENUVA at an infusion center? · Missing
|
5 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration (Concern About Continuing to Receive CABENUVA) by Other Quantitative Questionnaires at Month 3 and 8
Month 8- Do you have any concerns about continuing to receive CABENUVA at an infusion center? · Yes
|
3 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration (Concern About Continuing to Receive CABENUVA) by Other Quantitative Questionnaires at Month 3 and 8
Month 8- Do you have any concerns about continuing to receive CABENUVA at an infusion center? · No
|
34 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration (Concern About Continuing to Receive CABENUVA) by Other Quantitative Questionnaires at Month 3 and 8
Month 8- Do you have any concerns about continuing to receive CABENUVA at an infusion center? · Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: At Month 3 and 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Participants were asked about their views on the IC/ASA administration model (biggest concerns about continuing to receive CABENUVA at an infusion center).
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=41 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 8- Childcare during CABENUVA visits
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 3- The infusion center managing my pain or soreness from CABENUVA
|
1 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 3- The infusion center managing the side effects from CABENUVA
|
1 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 3- My doctor not knowing if I have a bad reaction
|
1 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 3- Scheduling upcoming CABENUVA visits
|
1 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 3- Transportation to the infusion center for the CABENUVA visits
|
1 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 3- Others at the clinic may find out that I am HIV positive
|
1 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 3- Other
|
1 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 3- The infusion center not aware of my other medical history
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 3- Infusion center not aware of my other medications and possible interactions
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 3- Rescheduling missed CABENUVA visits
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 3- Forgetting my appointments for the CABENUVA visits
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 3- Frequency of the required visits to infusion center clinic as well as my primary HIV doctor
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 3- Parking at the infusion center for CABENUVA visits
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 3- The infusion center hours for CABENUVA visits
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 3- Childcare during CABENUVA visits
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 3- Infusion center not being an HIV-specific clinic
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 3- Missing
|
5 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 8- The infusion center managing my pain or soreness from CABENUVA
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 8- The infusion center managing the side effects from CABENUVA
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 8- My doctor not knowing if I have a bad reaction
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 8- Scheduling upcoming CABENUVA visits
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 8- Transportation to the infusion center for the CABENUVA visits
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 8- Others at the clinic may find out that I am HIV positive
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 8- Other
|
3 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 8- The infusion center not aware of my other medical history
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 8- Infusion center not aware of my other medications and possible interactions
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 8- Rescheduling missed CABENUVA visits
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 8- Forgetting my appointments for the CABENUVA visits
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 8- Frequency of the required visits to infusion center clinic as well as my primary HIV doctor
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 8- Parking at the infusion center for CABENUVA visits
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 8- The infusion center hours for CABENUVA visits
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 8- Infusion center not being an HIV-specific clinic
|
0 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Other Quantitative Questionnaires at Month 3 and 8
Month 8- Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: At Month 1Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
The tailored HIV care provider/clinical staff questionnaire was developed specifically for this study and contains items regarding the provider's practice and experience, as well as their attitudes, expectations, and concerns regarding the use of CABENUVA/long-acting injectable administered by ICs/ASAs.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=3 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Extremely concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Moderately concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Somewhat concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Slightly concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Not at all concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Missing
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Extremely concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Moderately concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Somewhat concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Slightly concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Not at all concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Missing
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
Patients not being virologically suppressed due to missed injections · Extremely concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
Patients not being virologically suppressed due to missed injections · Moderately concerned
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
Patients not being virologically suppressed due to missed injections · Somewhat concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
Patients not being virologically suppressed due to missed injections · Slightly concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
Patients not being virologically suppressed due to missed injections · Not at all concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
Patients not being virologically suppressed due to missed injections · Missing
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
Being informed (in a timely manner) of adverse events · Extremely concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
Being informed (in a timely manner) of adverse events · Moderately concerned
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
Being informed (in a timely manner) of adverse events · Somewhat concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
Being informed (in a timely manner) of adverse events · Slightly concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
Being informed (in a timely manner) of adverse events · Not at all concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
Being informed (in a timely manner) of adverse events · Missing
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
IC's ability to address other care needs of patients presenting to CABENUVA appointments · Extremely concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
IC's ability to address other care needs of patients presenting to CABENUVA appointments · Moderately concerned
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
IC's ability to address other care needs of patients presenting to CABENUVA appointments · Somewhat concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
IC's ability to address other care needs of patients presenting to CABENUVA appointments · Slightly concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
IC's ability to address other care needs of patients presenting to CABENUVA appointments · Not at all concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 1
IC's ability to address other care needs of patients presenting to CABENUVA appointments · Missing
|
0 Participants
|
SECONDARY outcome
Timeframe: At Month 4Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=3 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Extremely concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Moderately concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Somewhat concerned
|
3 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Slightly concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Not at all concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Missing
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Extremely concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Moderately concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Somewhat concerned
|
3 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Slightly concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Not at all concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Missing
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
Patients not being virologically suppressed due to missed injections · Extremely concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
Patients not being virologically suppressed due to missed injections · Moderately concerned
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
Patients not being virologically suppressed due to missed injections · Somewhat concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
Patients not being virologically suppressed due to missed injections · Slightly concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
Patients not being virologically suppressed due to missed injections · Not at all concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
Patients not being virologically suppressed due to missed injections · Missing
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
Being informed (in a timely manner) of adverse events · Extremely concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
Being informed (in a timely manner) of adverse events · Moderately concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
Being informed (in a timely manner) of adverse events · Somewhat concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
Being informed (in a timely manner) of adverse events · Slightly concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
Being informed (in a timely manner) of adverse events · Not at all concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
Being informed (in a timely manner) of adverse events · Missing
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
IC's ability to address other care needs of patients presenting to CABENUVA appointments · Extremely concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
IC's ability to address other care needs of patients presenting to CABENUVA appointments · Moderately concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
IC's ability to address other care needs of patients presenting to CABENUVA appointments · Somewhat concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
IC's ability to address other care needs of patients presenting to CABENUVA appointments · Slightly concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
IC's ability to address other care needs of patients presenting to CABENUVA appointments · Not at all concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 4
IC's ability to address other care needs of patients presenting to CABENUVA appointments · Missing
|
0 Participants
|
SECONDARY outcome
Timeframe: At Month 8Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=3 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
IC's ability to address other care needs of patients presenting to CABENUVA appointments · Slightly concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Extremely concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Moderately concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Somewhat concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Slightly concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Not at all concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Missing
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Extremely concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Moderately concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Somewhat concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Slightly concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Not at all concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Missing
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Patients not being virologically suppressed due to missed injections · Extremely concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Patients not being virologically suppressed due to missed injections · Moderately concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Patients not being virologically suppressed due to missed injections · Somewhat concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Patients not being virologically suppressed due to missed injections · Slightly concerned
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Patients not being virologically suppressed due to missed injections · Not at all concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Patients not being virologically suppressed due to missed injections · Missing
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Being informed (in a timely manner) of adverse events · Extremely concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Being informed (in a timely manner) of adverse events · Moderately concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Being informed (in a timely manner) of adverse events · Somewhat concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Being informed (in a timely manner) of adverse events · Slightly concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Being informed (in a timely manner) of adverse events · Not at all concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Being informed (in a timely manner) of adverse events · Missing
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
IC's ability to address other care needs of patients presenting to CABENUVA appointments · Extremely concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
IC's ability to address other care needs of patients presenting to CABENUVA appointments · Moderately concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
IC's ability to address other care needs of patients presenting to CABENUVA appointments · Somewhat concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
IC's ability to address other care needs of patients presenting to CABENUVA appointments · Not at all concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
IC's ability to address other care needs of patients presenting to CABENUVA appointments · Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: Prior to Month 1 (Baseline)Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.
The tailored IC staff questionnaire was developed specifically for this study and contains items regarding the staff member's role at the IC, as well as their attitudes, concerns, and anticipated/implemented procedures regarding the use of CABENUVA/long-acting injectable administered by ICs. The IC/ASA staff members were asked to indicate their level of concern across 16 areas of potential concern, on a five-point scale from "not at all concerned" to "extremely concerned."
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=113 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of rescheduling appointments during correct treatment windows- Somewhat concerned
|
8 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Timely reporting of adverse events to HIV providers- Missing
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Understanding how to bridge patients on oral dose for planned missed doses- Extremely concerned
|
9 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Understanding how to bridge patients on oral dose for planned missed doses- Moderately concerned
|
16 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Understanding how to bridge patients on oral dose for planned missed doses- Somewhat concerned
|
17 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Understanding how to bridge patients on oral dose for planned missed doses- Slightly concerned
|
37 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Understanding how to bridge patients on oral dose for planned missed doses- Not at all concerned
|
33 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Understanding how to bridge patients on oral dose for planned missed doses-Missing
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of reporting abnormal lab results with HIV providers- Extremely concerned
|
9 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of reporting abnormal lab results with HIV providers- Moderately concerned
|
11 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of reporting abnormal lab results with HIV providers- Somewhat concerned
|
15 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of reporting abnormal lab results with HIV providers- Slightly concerned
|
22 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of reporting abnormal lab results with HIV providers- Not at all concerned
|
55 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of reporting abnormal lab results with HIV providers- Missing
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Understanding when to bridge patients on oral dose for planned missed doses- Extremely concerned
|
8 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Understanding when to bridge patients on oral dose for planned missed doses Moderately concerned
|
18 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Understanding when to bridge patients on oral dose for planned missed doses Somewhat concerned
|
20 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Understanding when to bridge patients on oral dose for planned missed doses- Slightly concerned
|
36 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Understanding when to bridge patients on oral dose for planned missed doses Not at all concerned
|
30 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Understanding when to bridge patients on oral dose for planned missed doses- Missing
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
IC's ability to address other care needs of patients at CABENUVA appointments- Extremely concerned
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
IC's ability to address other care needs of patients at CABENUVA appointments- Moderately concerned
|
19 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
IC's ability to address other care needs of patients at CABENUVA appointments- Somewhat concerned
|
20 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
IC's ability to address other care needs of patients at CABENUVA appointments- Slightly concerned
|
24 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
IC's ability to address other care needs of patients at CABENUVA appointments- Not at all concerned
|
42 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
IC's ability to address other care needs of patients at CABENUVA appointments- Missing
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Frequency of lab draws at the infusion center- Extremely concerned
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Frequency of lab draws at the infusion center- Moderately concerned
|
12 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Frequency of lab draws at the infusion center- Somewhat concerned
|
23 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Frequency of lab draws at the infusion center- Slightly concerned
|
23 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Frequency of lab draws at the infusion center- Not at all concerned
|
48 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Frequency of lab draws at the infusion center- Missing
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of rescheduling appointments during correct treatment windows- Extremely concerned
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of rescheduling appointments during correct treatment windows- Moderately concerned
|
5 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of rescheduling appointments during correct treatment windows- Slightly concerned
|
32 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of rescheduling appointments during correct treatment windows- Not at all concerned
|
63 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of rescheduling appointments during correct treatment windows- Missing
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of scheduling appointments during correct treatment windows- Extremely concerned
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of scheduling appointments during correct treatment windows- Moderately concerned
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of scheduling appointments during correct treatment windows- Somewhat concerned
|
10 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of scheduling appointments during correct treatment windows- Slightly concerned
|
25 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of scheduling appointments during correct treatment windows- Not at all concerned
|
69 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of scheduling appointments during correct treatment windows- Missing
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Answering patient questions between visits- Extremely concerned
|
3 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Answering patient questions between visits- Moderately concerned
|
10 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Answering patient questions between visits- Somewhat concerned
|
18 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Answering patient questions between visits- Slightly concerned
|
38 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Answering patient questions between visits- Not at all concerned
|
43 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Answering patient questions between visits- Missing
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of confirming patient insurance coverage- Extremely concerned
|
3 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of confirming patient insurance coverage- Moderately concerned
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of confirming patient insurance coverage- Somewhat- concerned
|
7 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of confirming patient insurance coverage- Slightly concerned
|
16 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of confirming patient insurance coverage- Not at all concerned
|
82 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of confirming patient insurance coverage- Missing
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Patient insurance coverage clearing for payment- Extremely concerned
|
3 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Patient insurance coverage clearing for payment- Moderately concerned
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Patient insurance coverage clearing for payment- Somewhat concerned
|
12 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Patient insurance coverage clearing for payment- Slightly concerned
|
17 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Patient insurance coverage clearing for payment- Not at all concerned
|
79 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Patient insurance coverage clearing for payment- Missing
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of patient injection-related pain/soreness- Extremely concerned
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of patient injection-related pain/soreness- Moderately concerned
|
5 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of patient injection-related pain/soreness- Somewhat concerned
|
10 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of patient injection-related pain/soreness- Slightly concerned
|
28 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of patient injection-related pain/soreness- Not at all concerned
|
67 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of patient injection-related pain/soreness- Missing
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of reporting of adverse events- Extremely concerned
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of reporting of adverse events- Moderately concerned
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of reporting of adverse events- Somewhat concerned
|
9 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of reporting of adverse events- Slightly concerned
|
25 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of reporting of adverse events- Not at all concerned
|
72 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Management of reporting of adverse events- Missing
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Patients' willingness to travel to an infusion center for each injection visit- Extremely concerned
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Patients' willingness to travel to an infusion center for each injection visit- Moderately concerned
|
10 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Patients' willingness to travel to an infusion center for each injection visit- Somewhat concerned
|
26 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Patients' willingness to travel to an infusion center for each injection visit- Slightly concerned
|
14 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Patients' willingness to travel to an infusion center for each injection visit- Not at all concerned
|
61 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Patients' willingness to travel to an infusion center for each injection visit- Missing
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Timely reporting of adverse events to HIV providers- Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Timely reporting of adverse events to HIV providers- Moderately concerned
|
5 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Timely reporting of adverse events to HIV providers- Somewhat concerned
|
5 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Timely reporting of adverse events to HIV providers- Slightly concerned
|
17 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Timely reporting of adverse events to HIV providers- Not at all concerned
|
85 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Timely reporting to the provider when a patient misses a CABENUVA visit- Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Timely reporting to the provider when a patient misses a CABENUVA visit- Moderately concerned
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Timely reporting to the provider when a patient misses a CABENUVA visit- Somewhat concerned
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Timely reporting to the provider when a patient misses a CABENUVA visit- Slightly concerned
|
21 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Timely reporting to the provider when a patient misses a CABENUVA visit- Not at all concerned
|
83 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Timely reporting to the provider when a patient misses a CABENUVA visit- Missing
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Timely reporting to the provider when a patient receives CABENUVA- Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Timely reporting to the provider when a patient receives CABENUVA- Moderately concerned
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Timely reporting to the provider when a patient receives CABENUVA- Somewhat concerned
|
7 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Timely reporting to the provider when a patient receives CABENUVA- Slightly concerned
|
16 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Timely reporting to the provider when a patient receives CABENUVA- Not at all concerned
|
88 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires Prior to Month 1
Timely reporting to the provider when a patient receives CABENUVA- Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: At Month 3Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.
The IC/ASA staff members were asked to indicate their level of concern across 16 areas of potential concern, on a five-point scale from "not at all concerned" to "extremely concerned."
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=38 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Understanding of how to provide patients with oral medication for planned missed doses · Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Understanding of how to provide patients with oral medication for planned missed doses · Moderately concerned
|
5 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Understanding of how to provide patients with oral medication for planned missed doses · Somewhat concerned
|
14 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Understanding of how to provide patients with oral medication for planned missed doses · Slightly concerned
|
7 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Understanding of how to provide patients with oral medication for planned missed doses · Not at all concerned
|
8 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Understanding of how to provide patients with oral medication for planned missed doses · Missing
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of reporting abnormal lab results with HIV providers · Extremely concerned
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of reporting abnormal lab results with HIV providers · Moderately concerned
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of reporting abnormal lab results with HIV providers · Somewhat concerned
|
3 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of reporting abnormal lab results with HIV providers · Slightly concerned
|
9 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of reporting abnormal lab results with HIV providers · Not at all concerned
|
17 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of reporting abnormal lab results with HIV providers · Missing
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Understanding of when patients should receive oral medication for planned missed doses · Extremely concerned
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Understanding of when patients should receive oral medication for planned missed doses · Moderately concerned
|
5 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Understanding of when patients should receive oral medication for planned missed doses · Somewhat concerned
|
8 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Understanding of when patients should receive oral medication for planned missed doses · Slightly concerned
|
9 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Understanding of when patients should receive oral medication for planned missed doses · Not at all concerned
|
11 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Understanding of when patients should receive oral medication for planned missed doses · Missing
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Managing patients presenting to CABENUVA appointments with other care needs to be addressed · Extremely concerned
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Managing patients presenting to CABENUVA appointments with other care needs to be addressed · Moderately concerned
|
3 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Managing patients presenting to CABENUVA appointments with other care needs to be addressed · Somewhat concerned
|
5 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Managing patients presenting to CABENUVA appointments with other care needs to be addressed · Slightly concerned
|
13 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Managing patients presenting to CABENUVA appointments with other care needs to be addressed · Not at all concerned
|
11 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Managing patients presenting to CABENUVA appointments with other care needs to be addressed · Missing
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Frequency of lab draws at the infusion center · Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Frequency of lab draws at the infusion center · Moderately concerned
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Frequency of lab draws at the infusion center · Somewhat concerned
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Frequency of lab draws at the infusion center · Slightly concerned
|
14 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Frequency of lab draws at the infusion center · Not at all concerned
|
12 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Frequency of lab draws at the infusion center · Missing
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of rescheduling appointments during correct treatment windows · Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of rescheduling appointments during correct treatment windows · Moderately concerned
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of rescheduling appointments during correct treatment windows · Somewhat concerned
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of rescheduling appointments during correct treatment windows · Slightly concerned
|
10 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of rescheduling appointments during correct treatment windows · Not at all concerned
|
19 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of rescheduling appointments during correct treatment windows · Missing
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of scheduling appointments during correct treatment windows · Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of scheduling appointments during correct treatment windows · Moderately concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of scheduling appointments during correct treatment windows · Somewhat concerned
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of scheduling appointments during correct treatment windows · Slightly concerned
|
7 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of scheduling appointments during correct treatment windows · Not at all concerned
|
25 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of scheduling appointments during correct treatment windows · Missing
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Answering patient questions between visits · Extremely concerned
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Answering patient questions between visits · Moderately concerned
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Answering patient questions between visits · Somewhat concerned
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Answering patient questions between visits · Slightly concerned
|
9 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Answering patient questions between visits · Not at all concerned
|
17 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Answering patient questions between visits · Missing
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of confirming patient insurance coverage · Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of confirming patient insurance coverage · Moderately concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of confirming patient insurance coverage · Somewhat concerned
|
3 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of confirming patient insurance coverage · Slightly concerned
|
11 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of confirming patient insurance coverage · Not at all concerned
|
20 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of confirming patient insurance coverage · Missing
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Patient insurance coverage clearing for payment · Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Patient insurance coverage clearing for payment · Moderately concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Patient insurance coverage clearing for payment · Somewhat concerned
|
5 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Patient insurance coverage clearing for payment · Slightly concerned
|
9 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Patient insurance coverage clearing for payment · Not at all concerned
|
20 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Patient insurance coverage clearing for payment · Missing
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of patient injection-related pain/soreness · Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of patient injection-related pain/soreness · Moderately concerned
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of patient injection-related pain/soreness · Somewhat concerned
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of patient injection-related pain/soreness · Slightly concerned
|
7 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of patient injection-related pain/soreness · Not at all concerned
|
19 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of patient injection-related pain/soreness · Missing
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of reporting of adverse events · Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of reporting of adverse events · Moderately concerned
|
3 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of reporting of adverse events · Somewhat concerned
|
3 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of reporting of adverse events · Slightly concerned
|
11 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of reporting of adverse events · Not at all concerned
|
17 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Management of reporting of adverse events · Missing
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Patients' willingness to travel to an infusion center for each injection visit · Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Patients' willingness to travel to an infusion center for each injection visit · Moderately concerned
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Patients' willingness to travel to an infusion center for each injection visit · Somewhat concerned
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Patients' willingness to travel to an infusion center for each injection visit · Slightly concerned
|
7 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Patients' willingness to travel to an infusion center for each injection visit · Not at all concerned
|
20 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Patients' willingness to travel to an infusion center for each injection visit · Missing
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Timely reporting of adverse events to HIV providers · Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Timely reporting of adverse events to HIV providers · Moderately concerned
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Timely reporting of adverse events to HIV providers · Somewhat concerned
|
5 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Timely reporting of adverse events to HIV providers · Slightly concerned
|
5 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Timely reporting of adverse events to HIV providers · Not at all concerned
|
23 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Timely reporting of adverse events to HIV providers · Missing
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Timely reporting to the provider when a patient misses a CABENUVA visit · Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Timely reporting to the provider when a patient misses a CABENUVA visit · Moderately concerned
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Timely reporting to the provider when a patient misses a CABENUVA visit · Somewhat concerned
|
5 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Timely reporting to the provider when a patient misses a CABENUVA visit · Slightly concerned
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Timely reporting to the provider when a patient misses a CABENUVA visit · Not at all concerned
|
22 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Timely reporting to the provider when a patient misses a CABENUVA visit · Missing
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Timely reporting to the provider when a patient receives CABENUVA · Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Timely reporting to the provider when a patient receives CABENUVA · Moderately concerned
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Timely reporting to the provider when a patient receives CABENUVA · Somewhat concerned
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Timely reporting to the provider when a patient receives CABENUVA · Slightly concerned
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Timely reporting to the provider when a patient receives CABENUVA · Not at all concerned
|
26 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants Assessed by Other Quantitative Questionnaires at Month 3
Timely reporting to the provider when a patient receives CABENUVA · Missing
|
4 Participants
|
SECONDARY outcome
Timeframe: At Month 8Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.
The IC/ASA staff members were asked to indicate their level of concern across 16 areas of potential concern, on a five-point scale from "not at all concerned" to "extremely concerned."
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=26 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of reporting abnormal lab results with HIV providers · Missing
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Frequency of lab draws at the infusion center · Moderately concerned
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Understanding of when patients should receive oral medication for planned missed doses · Somewhat concerned
|
5 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Understanding of when patients should receive oral medication for planned missed doses · Slightly concerned
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Understanding of when patients should receive oral medication for planned missed doses · Not at all concerned
|
7 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Understanding of when patients should receive oral medication for planned missed doses · Missing
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Managing patients presenting to CABENUVA appointments with other care needs to be addressed · Extremely concerned
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Managing patients presenting to CABENUVA appointments with other care needs to be addressed · Moderately concerned
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Managing patients presenting to CABENUVA appointments with other care needs to be addressed · Somewhat concerned
|
3 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Managing patients presenting to CABENUVA appointments with other care needs to be addressed · Slightly concerned
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Managing patients presenting to CABENUVA appointments with other care needs to be addressed · Not at all concerned
|
9 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Managing patients presenting to CABENUVA appointments with other care needs to be addressed · Missing
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Frequency of lab draws at the infusion center · Extremely concerned
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Frequency of lab draws at the infusion center · Somewhat concerned
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Frequency of lab draws at the infusion center · Slightly concerned
|
7 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Frequency of lab draws at the infusion center · Not at all concerned
|
9 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Frequency of lab draws at the infusion center · Missing
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of rescheduling appointments during correct treatment windows · Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of rescheduling appointments during correct treatment windows · Moderately concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of rescheduling appointments during correct treatment windows · Somewhat concerned
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of rescheduling appointments during correct treatment windows · Slightly concerned
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of rescheduling appointments during correct treatment windows · Not at all concerned
|
10 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of rescheduling appointments during correct treatment windows · Missing
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of scheduling appointments during correct treatment windows · Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of scheduling appointments during correct treatment windows · Moderately concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of scheduling appointments during correct treatment windows · Somewhat concerned
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of scheduling appointments during correct treatment windows · Slightly concerned
|
8 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of scheduling appointments during correct treatment windows · Not at all concerned
|
10 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of scheduling appointments during correct treatment windows · Missing
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Answering patient questions between visits · Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Answering patient questions between visits · Moderately concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Answering patient questions between visits · Somewhat concerned
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Answering patient questions between visits · Slightly concerned
|
5 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Answering patient questions between visits · Not at all concerned
|
11 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Answering patient questions between visits · Missing
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of confirming patient insurance coverage · Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of confirming patient insurance coverage · Moderately concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of confirming patient insurance coverage · Somewhat concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of confirming patient insurance coverage · Slightly concerned
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of confirming patient insurance coverage · Not at all concerned
|
16 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of confirming patient insurance coverage · Missing
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Patient insurance coverage clearing for payment · Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Patient insurance coverage clearing for payment · Moderately concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Patient insurance coverage clearing for payment · Somewhat concerned
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Patient insurance coverage clearing for payment · Slightly concerned
|
5 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Patient insurance coverage clearing for payment · Not at all concerned
|
14 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Patient insurance coverage clearing for payment · Missing
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of patient injection-related pain/soreness · Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of patient injection-related pain/soreness · Moderately concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of patient injection-related pain/soreness · Somewhat concerned
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of patient injection-related pain/soreness · Slightly concerned
|
5 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of patient injection-related pain/soreness · Not at all concerned
|
13 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of patient injection-related pain/soreness · Missing
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of reporting of adverse events · Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of reporting of adverse events · Moderately concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of reporting of adverse events · Somewhat concerned
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of reporting of adverse events · Slightly concerned
|
7 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of reporting of adverse events · Not at all concerned
|
12 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of reporting of adverse events · Missing
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Patients' willingness to travel to an infusion center for each injection visit · Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Patients' willingness to travel to an infusion center for each injection visit · Moderately concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Patients' willingness to travel to an infusion center for each injection visit · Somewhat concerned
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Patients' willingness to travel to an infusion center for each injection visit · Slightly concerned
|
3 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Patients' willingness to travel to an infusion center for each injection visit · Not at all concerned
|
15 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Patients' willingness to travel to an infusion center for each injection visit · Missing
|
7 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Timely reporting of adverse events to HIV providers · Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Timely reporting of adverse events to HIV providers · Moderately concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Timely reporting of adverse events to HIV providers · Somewhat concerned
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Timely reporting of adverse events to HIV providers · Slightly concerned
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Timely reporting of adverse events to HIV providers · Not at all concerned
|
13 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Timely reporting of adverse events to HIV providers · Missing
|
7 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Timely reporting to the provider when a patient misses a CABENUVA visit · Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Timely reporting to the provider when a patient misses a CABENUVA visit · Moderately concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Timely reporting to the provider when a patient misses a CABENUVA visit · Somewhat concerned
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Timely reporting to the provider when a patient misses a CABENUVA visit · Slightly concerned
|
5 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Timely reporting to the provider when a patient misses a CABENUVA visit · Not at all concerned
|
13 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Timely reporting to the provider when a patient misses a CABENUVA visit · Missing
|
7 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Timely reporting to the provider when a patient receives CABENUVA · Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Timely reporting to the provider when a patient receives CABENUVA · Moderately concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Timely reporting to the provider when a patient receives CABENUVA · Somewhat concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Timely reporting to the provider when a patient receives CABENUVA · Slightly concerned
|
3 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Timely reporting to the provider when a patient receives CABENUVA · Not at all concerned
|
16 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Timely reporting to the provider when a patient receives CABENUVA · Missing
|
7 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Understanding of how to provide patients with oral medication for planned missed doses · Extremely concerned
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Understanding of how to provide patients with oral medication for planned missed doses · Moderately concerned
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Understanding of how to provide patients with oral medication for planned missed doses · Somewhat concerned
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Understanding of how to provide patients with oral medication for planned missed doses · Slightly concerned
|
3 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Understanding of how to provide patients with oral medication for planned missed doses · Not at all concerned
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Understanding of how to provide patients with oral medication for planned missed doses · Missing
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of reporting abnormal lab results with HIV providers · Extremely concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of reporting abnormal lab results with HIV providers · Moderately concerned
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of reporting abnormal lab results with HIV providers · Somewhat concerned
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of reporting abnormal lab results with HIV providers · Slightly concerned
|
9 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Management of reporting abnormal lab results with HIV providers · Not at all concerned
|
10 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Understanding of when patients should receive oral medication for planned missed doses · Extremely concerned
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Other Quantitative Questionnaires at Month 8
Understanding of when patients should receive oral medication for planned missed doses · Moderately concerned
|
1 Participants
|
SECONDARY outcome
Timeframe: At Month 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Qualitative interviews were conducted at Month 8 to evaluate the opinions of participants on the feasibility of CABENUVA administration at IC/ASA.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=28 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Qualitative Interviews at Month 8
Good facilities/environment
|
8 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Qualitative Interviews at Month 8
Professional and caring staff
|
23 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Qualitative Interviews at Month 8
Consistency of providers
|
2 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Qualitative Interviews at Month 8
Protects participants' privacy
|
14 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Qualitative Interviews at Month 8
Scheduling flexibility
|
4 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Qualitative Interviews at Month 8
Appointment reminders
|
1 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Qualitative Interviews at Month 8
Quick and easy administration process
|
6 Participants
|
|
Number of Participants Assessed for Feasibility of CABENUVA Administration by Qualitative Interviews at Month 8
Hassle-free for participants
|
1 Participants
|
SECONDARY outcome
Timeframe: At Month 8Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
Qualitative interviews were conducted at Month 8 to evaluate the general opinion of HIV care providers on the feasibility of referring participants to receive CABENUVA at the IC/ASA.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=2 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Qualitative Interviews at Month 8
Only if insurance requires
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Feasibility of CABENUVA Administration in Participants by Qualitative Interviews at Month 8
Positive experience thus far
|
1 Participants
|
SECONDARY outcome
Timeframe: At Month 8Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.
Qualitative interviews were conducted at Month 8 to evaluate the general opinion of IC/ ASA staff on feasibility of CABENUVA administration at the IC/ASA.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=12 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Qualitative Interviews at Month 8
Fits into existing process and practices
|
12 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Qualitative Interviews at Month 8
Administration of injection gets easier with experience
|
3 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Qualitative Interviews at Month 8
Facilitates implementation
|
12 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Qualitative Interviews at Month 8
Scheduling system work arounds to accommodate visit window
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Qualitative Interviews at Month 8
Modifying visit duration to account for all the pieces of administering CABENUVA
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Feasibility of CABENUVA Administration in Participants by Qualitative Interviews at Month 8
Shortage of private rooms
|
4 Participants
|
SECONDARY outcome
Timeframe: Up to and including Month 8Population: Data was collected at the clinic level and analysis was performed on the Clinics that consented one or more participants for administration of intervention.
Composite score of feasibility process was calculated as the mean of the following four scores: FIM Score, Consent Rate, Show Rate, and Return Rate at Visit, on a 0 to 100 scale, where higher numbers correspond to better feasibility.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=14 Clinics
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Composite Score of Feasibility Process Indications
|
80.8 Scores on a scale
Standard Deviation 5.46
|
SECONDARY outcome
Timeframe: Baseline (Month 1) and at Month 8Population: Data was collected at the clinic level and analysis was performed on the Clinics that consented one or more participants for administration of intervention.
This outcome measure was planned to evaluate change in composite score from baseline to month 8 according to the protocol. The composite score was however not evaluated as a change over time but as a point in time at month 8 as the components of each of the feasibility composite score (FIM score, consent rate, show rate and return rate) were captured at different time intervals.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=14 Clinics
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Change in Composite Score and Each Item of Composite Score Over Time
FIM score
|
84.7 Scores on a scale
Standard Deviation 17.96
|
|
Change in Composite Score and Each Item of Composite Score Over Time
Consent rate
|
52.3 Scores on a scale
Standard Deviation 25.73
|
|
Change in Composite Score and Each Item of Composite Score Over Time
Show rate
|
93.6 Scores on a scale
Standard Deviation 10.49
|
|
Change in Composite Score and Each Item of Composite Score Over Time
Return rate
|
92.7 Scores on a scale
Standard Deviation 13.92
|
SECONDARY outcome
Timeframe: Months 1 (Baseline), 4, and 8Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
AIM was employed to evaluate the acceptability of CABENUVA administration at Infusion Centers/ ASAs. Higher scores for AIM indicate greater acceptability, where each item was scored from 1 to 5: Completely disagree (score=1), disagree (score=2), neither agree or disagree (score=3), agree (score=4), completely agree (score=5).
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=2 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of HIV Care Providers Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the Acceptability of Intervention Measure (AIM)
At Month 1 (baseline)
|
1 Participants
|
|
Number of HIV Care Providers Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the Acceptability of Intervention Measure (AIM)
At month 4
|
2 Participants
|
|
Number of HIV Care Providers Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the Acceptability of Intervention Measure (AIM)
At month 8
|
1 Participants
|
SECONDARY outcome
Timeframe: Month 1 (Baseline), 3 and 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
AIM were employed to evaluate the acceptability of CABENUVA administration at Infusion Centers/ ASAs. Higher scores for AIM indicate greater acceptability, where each item was scored from 1 to 5: Completely disagree (score=1), disagree (score=2), neither agree or disagree (score=3), agree (score=4), completely agree (score=5).
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=35 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the AIM
At Month 1 (baseline)
|
35 Participants
|
|
Number of Participants Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the AIM
At month 3
|
32 Participants
|
|
Number of Participants Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the AIM
At month 8
|
33 Participants
|
SECONDARY outcome
Timeframe: Prior to Month 1 (Baseline), and at Month 3 and 8Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.
AIM were employed to evaluate the acceptability of CABENUVA administration at Infusion Centers/ ASAs. Higher scores for AIM indicate greater acceptability, where each item was scored from 1 to 5: Completely disagree (score=1), disagree (score=2), neither agree or disagree (score=3), agree (score=4), completely agree (score=5).
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=47 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of IC/ ASA Staff Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the AIM
Prior to Month 1 (baseline)
|
47 Participants
|
|
Number of IC/ ASA Staff Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the AIM
At month 3
|
13 Participants
|
|
Number of IC/ ASA Staff Who Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the AIM
At month 8
|
13 Participants
|
SECONDARY outcome
Timeframe: Month 1 (Baseline), at Months 4 and 8Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
The mean score for acceptability of the intervention is calculated by averaging the responses from 4 items. The responses were scored based on a scale of 1 to 5 where 1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=3 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Change in AIM Score Over Time in HIV Care Providers at Month 4 and 8
From baseline to month 4
|
0.33 Scores on a scale
Standard Deviation 0.382
|
|
Change in AIM Score Over Time in HIV Care Providers at Month 4 and 8
From baseline to month 8
|
0.25 Scores on a scale
Standard Deviation 1.414
|
SECONDARY outcome
Timeframe: Month 1 (Baseline), at Months 3 and 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
The mean score for acceptability of the intervention is calculated by averaging the responses from 4 items. The responses were scored based on a scale of 1 to 5 where 1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=36 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Change in AIM Score Over Time in Participants at Month 3 and 8
From baseline to month 3
|
0.03 Scores on a scale
Standard Deviation 0.558
|
|
Change in AIM Score Over Time in Participants at Month 3 and 8
From baseline to month 8
|
0.00 Scores on a scale
Standard Deviation 0.604
|
SECONDARY outcome
Timeframe: Month 1 (Baseline), at Months 3 and 8Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.
The mean score for acceptability of the intervention is calculated by averaging the responses from 4 items. The responses were scored based on a scale of 1 to 5 where 1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=34 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Change in AIM Score Over Time in IC/ ASA Staff at Month 3 and 8
From baseline to month 3
|
-0.24 Scores on a scale
Standard Deviation 0.809
|
|
Change in AIM Score Over Time in IC/ ASA Staff at Month 3 and 8
From baseline to month 8
|
-0.03 Scores on a scale
Standard Deviation 0.778
|
SECONDARY outcome
Timeframe: At Months 1, 4 and 8Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=3 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 4- How acceptable was the overall process of interacting with the infusion center so far? · A little acceptable
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 1- How acceptable was the overall process of interacting with the infusion center so far? · Very acceptable
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 1- How acceptable was the overall process of interacting with the infusion center so far? · Somewhat acceptable
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 1- How acceptable was the overall process of interacting with the infusion center so far? · A little acceptable
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 1- How acceptable was the overall process of interacting with the infusion center so far? · Neutral
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 1- How acceptable was the overall process of interacting with the infusion center so far? · A little unacceptable
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 1- How acceptable was the overall process of interacting with the infusion center so far? · Somewhat unacceptable
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 1- How acceptable was the overall process of interacting with the infusion center so far? · Very unacceptable
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 1- How acceptable was the overall process of interacting with the infusion center so far? · I have not interacted with the infusion center yet.
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 1- How acceptable was the overall process of interacting with the infusion center so far? · Missing
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 4- How acceptable was the overall process of interacting with the infusion center so far? · Very acceptable
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 4- How acceptable was the overall process of interacting with the infusion center so far? · Somewhat acceptable
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 4- How acceptable was the overall process of interacting with the infusion center so far? · Neutral
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 4- How acceptable was the overall process of interacting with the infusion center so far? · A little unacceptable
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 4- How acceptable was the overall process of interacting with the infusion center so far? · Somewhat unacceptable
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 4- How acceptable was the overall process of interacting with the infusion center so far? · Very unacceptable
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 4- How acceptable was the overall process of interacting with the infusion center so far? · I have not interacted with the infusion center yet.
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 4- How acceptable was the overall process of interacting with the infusion center so far? · Missing
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 8- How acceptable was the overall process of interacting with the infusion center so far? · Very acceptable
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 8- How acceptable was the overall process of interacting with the infusion center so far? · Somewhat acceptable
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 8- How acceptable was the overall process of interacting with the infusion center so far? · A little acceptable
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 8- How acceptable was the overall process of interacting with the infusion center so far? · Neutral
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 8- How acceptable was the overall process of interacting with the infusion center so far? · A little unacceptable
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 8- How acceptable was the overall process of interacting with the infusion center so far? · Somewhat unacceptable
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 8- How acceptable was the overall process of interacting with the infusion center so far? · Very unacceptable
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 8- How acceptable was the overall process of interacting with the infusion center so far? · I have not interacted with the infusion center yet.
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 1, 4 and 8
Month 8- How acceptable was the overall process of interacting with the infusion center so far? · Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: At Months 1, 3 and 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
The participants were asked how acceptable it was to come to the IC/ASA for CABENUVA using a 7-point scale from "very acceptable" to "very unacceptable" where 1= very acceptable, 2= somewhat acceptable, 3= a little acceptable, 4= neutral, 5= a little unacceptable, 6= somewhat unacceptable and 7= very unacceptable.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=44 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8
Month 1- How acceptable is it to you to come to the infusion center for CABENUVA? · Very acceptable
|
34 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8
Month 1- How acceptable is it to you to come to the infusion center for CABENUVA? · Somewhat acceptable
|
6 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8
Month 1- How acceptable is it to you to come to the infusion center for CABENUVA? · A little acceptable
|
0 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8
Month 1- How acceptable is it to you to come to the infusion center for CABENUVA? · Neutral
|
2 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8
Month 1- How acceptable is it to you to come to the infusion center for CABENUVA? · A little unacceptable
|
0 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8
Month 1- How acceptable is it to you to come to the infusion center for CABENUVA? · Somewhat unacceptable
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8
Month 1- How acceptable is it to you to come to the infusion center for CABENUVA? · Very unacceptable
|
0 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8
Month 1- How acceptable is it to you to come to the infusion center for CABENUVA? · Missing
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8
Month 3- How acceptable is it to you to come to the infusion center for CABENUVA? · Very acceptable
|
24 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8
Month 3- How acceptable is it to you to come to the infusion center for CABENUVA? · Somewhat acceptable
|
9 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8
Month 3- How acceptable is it to you to come to the infusion center for CABENUVA? · A little acceptable
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8
Month 3- How acceptable is it to you to come to the infusion center for CABENUVA? · Neutral
|
0 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8
Month 3- How acceptable is it to you to come to the infusion center for CABENUVA? · A little unacceptable
|
0 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8
Month 3- How acceptable is it to you to come to the infusion center for CABENUVA? · Somewhat unacceptable
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8
Month 3- How acceptable is it to you to come to the infusion center for CABENUVA? · Very unacceptable
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8
Month 3- How acceptable is it to you to come to the infusion center for CABENUVA? · Missing
|
5 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8
Month 8- How acceptable is it to you to come to the infusion center for CABENUVA? · Very acceptable
|
23 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8
Month 8- How acceptable is it to you to come to the infusion center for CABENUVA? · Somewhat acceptable
|
8 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8
Month 8- How acceptable is it to you to come to the infusion center for CABENUVA? · A little acceptable
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8
Month 8- How acceptable is it to you to come to the infusion center for CABENUVA? · Neutral
|
4 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8
Month 8- How acceptable is it to you to come to the infusion center for CABENUVA? · A little unacceptable
|
0 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8
Month 8- How acceptable is it to you to come to the infusion center for CABENUVA? · Somewhat unacceptable
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8
Month 8- How acceptable is it to you to come to the infusion center for CABENUVA? · Very unacceptable
|
0 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ ASA by Other Quantitative Questionnaire in at Months 1, 3 and 8
Month 8- How acceptable is it to you to come to the infusion center for CABENUVA? · Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: Prior to Month 1 (Baseline)Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=113 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire Prior to Month 1
Extremely concerned
|
6 Participants
|
|
Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire Prior to Month 1
Moderately concerned
|
13 Participants
|
|
Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire Prior to Month 1
Somewhat concerned
|
22 Participants
|
|
Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire Prior to Month 1
Slightly concerned
|
21 Participants
|
|
Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire Prior to Month 1
Not at all concerned
|
51 Participants
|
|
Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire Prior to Month 1
Missing
|
0 Participants
|
SECONDARY outcome
Timeframe: At Months 3 and 8Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=38 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8
Month 3- Concern from a personal safety perspective about administering CABENUVA to people with HIV? · Extremely concerned
|
0 Participants
|
|
Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8
Month 3- Concern from a personal safety perspective about administering CABENUVA to people with HIV? · Moderately concerned
|
0 Participants
|
|
Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8
Month 3- Concern from a personal safety perspective about administering CABENUVA to people with HIV? · Somewhat concerned
|
5 Participants
|
|
Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8
Month 3- Concern from a personal safety perspective about administering CABENUVA to people with HIV? · Slightly concerned
|
6 Participants
|
|
Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8
Month 3- Concern from a personal safety perspective about administering CABENUVA to people with HIV? · Not at all concerned
|
22 Participants
|
|
Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8
Month 3- Concern from a personal safety perspective about administering CABENUVA to people with HIV? · Unsure/not applicable to role
|
1 Participants
|
|
Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8
Month 3- Concern from a personal safety perspective about administering CABENUVA to people with HIV? · Missing
|
4 Participants
|
|
Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8
Month 8- Concern from a personal safety perspective about administering CABENUVA to people with HIV? · Extremely concerned
|
0 Participants
|
|
Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8
Month 8- Concern from a personal safety perspective about administering CABENUVA to people with HIV? · Moderately concerned
|
1 Participants
|
|
Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8
Month 8- Concern from a personal safety perspective about administering CABENUVA to people with HIV? · Somewhat concerned
|
3 Participants
|
|
Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8
Month 8- Concern from a personal safety perspective about administering CABENUVA to people with HIV? · Slightly concerned
|
4 Participants
|
|
Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8
Month 8- Concern from a personal safety perspective about administering CABENUVA to people with HIV? · Not at all concerned
|
11 Participants
|
|
Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8
Month 8- Concern from a personal safety perspective about administering CABENUVA to people with HIV? · Unsure/not applicable to role
|
1 Participants
|
|
Number of IC/ ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ ASA by Other Quantitative Questionnaire at Months 3 and 8
Month 8- Concern from a personal safety perspective about administering CABENUVA to people with HIV? · Missing
|
6 Participants
|
SECONDARY outcome
Timeframe: At Month 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Participants were asked about their opinion on acceptability of CABENUVA administration at the IC/ASA.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=28 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ASA by Qualitative Interviews at Month 8
Good facilities/environment
|
8 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ASA by Qualitative Interviews at Month 8
Professional and caring staff
|
23 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ASA by Qualitative Interviews at Month 8
Consistency of providers
|
2 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ASA by Qualitative Interviews at Month 8
Protects participants' privacy
|
14 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ASA by Qualitative Interviews at Month 8
Scheduling flexibility
|
4 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ASA by Qualitative Interviews at Month 8
Appointment reminders
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ASA by Qualitative Interviews at Month 8
Quick and easy administration process
|
6 Participants
|
|
Number of Participants Assessed for Acceptability of CABENUVA Administration at IC/ASA by Qualitative Interviews at Month 8
Hassle-free for participants
|
1 Participants
|
SECONDARY outcome
Timeframe: At Month 8Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
HIV care providers were asked about their opinion on the acceptability of participants receiving CABENUVA at the IC/ASA.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=2 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of HIV Care Providers Assessed for Acceptability of CABENUVA Administration in Participants at IC/ASA by Qualitative Interviews at Month 8
|
2 Participants
|
SECONDARY outcome
Timeframe: At Month 8Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.
IC/ASA staff were asked about their opinion on the acceptability of administering CABENUVA at an IC/ASA.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=12 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of IC/ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ASA by Qualitative Interviews at Month 8
Learned more about CABENUVA
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ASA by Qualitative Interviews at Month 8
Improved outlook about CABENUVA
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ASA by Qualitative Interviews at Month 8
Ease of administration over time
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ASA by Qualitative Interviews at Month 8
Quick and easy administration process
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Acceptability of CABENUVA Administration in Participants at IC/ASA by Qualitative Interviews at Month 8
Easy to integrate into IC/ASA workflow
|
4 Participants
|
SECONDARY outcome
Timeframe: Prior to Month 1 (Baseline), and at Month 3 and 6Population: Analysis was performed on the Expert Panel which includes any Expert Panel member who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=8 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Expert Panel That Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM Scale
Prior to Month 1 (Baseline)
|
5 Participants
|
|
Number of Expert Panel That Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM Scale
Month 3
|
5 Participants
|
|
Number of Expert Panel That Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the FIM Scale
Month 6
|
5 Participants
|
SECONDARY outcome
Timeframe: Prior to Month 1 (Baseline), and at Month 3 and 6Population: Analysis was performed on the Expert Panel which includes any Expert Panel member who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=8 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Expert Panel That Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the AIM Scale
Prior to Month 1 (Baseline)
|
6 Participants
|
|
Number of Expert Panel That Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the AIM Scale
Month 3
|
6 Participants
|
|
Number of Expert Panel That Agree or Completely Agree (a Score of 4 or Higher) Across All Items on the AIM Scale
Month 6
|
6 Participants
|
SECONDARY outcome
Timeframe: Prior to Month 1 (Baseline) and Up to Month 6Population: Analysis was performed on the Expert Panel which includes any Expert Panel member who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=8 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Change in FIM Score of Expert Panel Over Time Through Month 6
Prior to Month 1 (Baseline)
|
4.00 Scores on a scale
Standard Deviation 0.991
|
|
Change in FIM Score of Expert Panel Over Time Through Month 6
Month 6
|
4.46 Scores on a scale
Standard Deviation 0.534
|
SECONDARY outcome
Timeframe: Prior to Month 1 (Baseline) and Up to Month 6Population: Analysis was performed on the Expert Panel which includes any Expert Panel member who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=8 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Change in AIM Score of Expert Panel Over Time Through Month 6
Prior to Month 1 (Baseline)
|
4.22 Scores on a scale
Standard Deviation 0.619
|
|
Change in AIM Score of Expert Panel Over Time Through Month 6
Month 6
|
4.46 Scores on a scale
Standard Deviation 0.510
|
SECONDARY outcome
Timeframe: Prior to Month 1 (Baseline)Population: Analysis was performed on the Expert Panel which includes any Expert Panel member who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=8 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance Coverage for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1
What is your preference for who will conduct the insurance benefit verification? · Infusion Center Staff
|
4 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance Coverage for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1
What is your preference for who will conduct the insurance benefit verification? · Unsure/Not applicable to role
|
2 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance Coverage for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1
What is your preference for who will conduct the insurance benefit verification? · HIV Provider/ Clinic Staff
|
1 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance Coverage for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1
What is your preference for who will conduct the insurance benefit verification? · ViiV Connect (reimbursement hub)
|
1 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance Coverage for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1
What is your preference for who will conduct the insurance benefit verification? · Missing
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance Coverage for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1
What is your preference for who notifies the patient about insurance coverage? · Infusion Center Staff
|
6 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance Coverage for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1
What is your preference for who notifies the patient about insurance coverage? · Unsure/Not applicable to role
|
2 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance Coverage for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1
What is your preference for who notifies the patient about insurance coverage? · HIV Provider/ Clinic Staff
|
2 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance Coverage for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1
What is your preference for who notifies the patient about insurance coverage? · ViiV Connect (reimbursement hub)
|
NA Participants
This category is not applicable to this question.
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance Coverage for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1
What is your preference for who notifies the patient about insurance coverage? · Missing
|
0 Participants
|
SECONDARY outcome
Timeframe: Prior to Month 1 (Baseline)Population: Analysis was performed on the Expert Panel which includes any Expert Panel member who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=8 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1
Preferred mode of communication about AEs from IC to HIV provider · Other
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1
Preferred mode of communication between HIV provider and IC when a patient discontinues CABENUVA · Fax
|
5 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1
Preferred mode of communication between HIV provider and IC when a patient discontinues CABENUVA · Phone call
|
2 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1
Preferred mode of communication between HIV provider and IC when a patient discontinues CABENUVA · Secure Electronic Medical Record message
|
1 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1
Preferred mode of communication between HIV provider and IC when a patient discontinues CABENUVA · Text
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1
Preferred mode of communication between HIV provider and IC when a patient discontinues CABENUVA · Email
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1
Preferred mode of communication between HIV provider and IC when a patient discontinues CABENUVA · Other
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1
Preferred mode of communication between HIV provider and IC when a patient discontinues CABENUVA · Unsure/ Not applicable to role
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1
Preferred mode of communication between HIV provider and IC when a patient discontinues CABENUVA · Missing
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1
Preferred mode of communication about AEs from IC to HIV provider · Fax
|
5 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1
Preferred mode of communication about AEs from IC to HIV provider · Phone call
|
2 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1
Preferred mode of communication about AEs from IC to HIV provider · Secure Electronic Medical Record message
|
1 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1
Preferred mode of communication about AEs from IC to HIV provider · Text
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1
Preferred mode of communication about AEs from IC to HIV provider · Email
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1
Preferred mode of communication about AEs from IC to HIV provider · Unsure/ Not applicable to role
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Communication for CABENUVA Administration in Participants by Quantitative Questionnaires Prior to Month 1
Preferred mode of communication about AEs from IC to HIV provider · Missing
|
0 Participants
|
SECONDARY outcome
Timeframe: Prior to Month 1 (Baseline)Population: Analysis was performed on the Expert Panel which includes any Expert Panel member who completed any portion of any questionnaire at the specified timepoint.
In this outcome measure, Expert Panel members were asked about their views on the IC/ASA administration model (for patients receiving CABENUVA injections at the infusion center, what is the preferred interval of time for patients to be seen by their HIV provider).
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=8 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration (Interval of Time) in Participants by Quantitative Questionnaires Prior to Month 1
Never/ not needed
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration (Interval of Time) in Participants by Quantitative Questionnaires Prior to Month 1
Every month
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration (Interval of Time) in Participants by Quantitative Questionnaires Prior to Month 1
Every 2 months
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration (Interval of Time) in Participants by Quantitative Questionnaires Prior to Month 1
Every 3 months
|
1 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration (Interval of Time) in Participants by Quantitative Questionnaires Prior to Month 1
Every 4 months
|
1 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration (Interval of Time) in Participants by Quantitative Questionnaires Prior to Month 1
Every 6 months
|
2 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration (Interval of Time) in Participants by Quantitative Questionnaires Prior to Month 1
Yearly
|
2 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration (Interval of Time) in Participants by Quantitative Questionnaires Prior to Month 1
As needed (i.e., when an adverse event occurs)
|
1 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration (Interval of Time) in Participants by Quantitative Questionnaires Prior to Month 1
Unsure/ Not applicable to role
|
2 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration (Interval of Time) in Participants by Quantitative Questionnaires Prior to Month 1
Missing
|
0 Participants
|
SECONDARY outcome
Timeframe: Prior to Month 1 (Baseline)Population: Analysis was performed on the Expert Panel which includes any Expert Panel member who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=8 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Referring Participants for CABENUVA Administration by Quantitative Questionnaires Prior to Month 1
Fax
|
5 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Referring Participants for CABENUVA Administration by Quantitative Questionnaires Prior to Month 1
Unsure/Not applicable to role
|
2 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Referring Participants for CABENUVA Administration by Quantitative Questionnaires Prior to Month 1
Secure Electronic Medical Record message
|
1 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Referring Participants for CABENUVA Administration by Quantitative Questionnaires Prior to Month 1
Phone call
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Referring Participants for CABENUVA Administration by Quantitative Questionnaires Prior to Month 1
Email
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Referring Participants for CABENUVA Administration by Quantitative Questionnaires Prior to Month 1
Other
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Referring Participants for CABENUVA Administration by Quantitative Questionnaires Prior to Month 1
Missing
|
0 Participants
|
SECONDARY outcome
Timeframe: At Month 3Population: Analysis was performed on the Expert Panel which includes any Expert Panel member who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=7 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3
Acceptability of communication between yourself and the IC during the oral lead-in phase? · Very acceptable
|
1 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3
Acceptability of communication between yourself and the IC during the oral lead-in phase? · Somewhat acceptable
|
1 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3
Acceptability of insurance verification/confirmation process for patients referred to the IC · Extremely acceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3
Acceptability of insurance verification/confirmation process for patients referred to the IC · Very acceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3
Acceptability of insurance verification/confirmation process for patients referred to the IC · Somewhat acceptable
|
1 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3
Acceptability of insurance verification/confirmation process for patients referred to the IC · Neither acceptable nor unacceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3
Acceptability of insurance verification/confirmation process for patients referred to the IC · Somewhat unacceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3
Acceptability of insurance verification/confirmation process for patients referred to the IC · Very unacceptable
|
1 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3
Acceptability of insurance verification/confirmation process for patients referred to the IC · Extremely unacceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3
Acceptability of insurance verification/confirmation process for patients referred to the IC · I do not have knowledge of/not involved in this process
|
1 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3
How acceptable has the process been for relaying insurance coverage information to patients? · Extremely acceptable
|
1 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3
How acceptable has the process been for relaying insurance coverage information to patients? · Very acceptable
|
1 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3
How acceptable has the process been for relaying insurance coverage information to patients? · Somewhat acceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3
How acceptable has the process been for relaying insurance coverage information to patients? · Neither acceptable nor unacceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3
How acceptable has the process been for relaying insurance coverage information to patients? · Somewhat unacceptable
|
1 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3
How acceptable has the process been for relaying insurance coverage information to patients? · Very unacceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3
How acceptable has the process been for relaying insurance coverage information to patients? · Extremely unacceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3
How acceptable has the process been for relaying insurance coverage information to patients? · I do not have knowledge of/not involved in this process
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3
Acceptability of communication between yourself and the IC during the oral lead-in phase? · Extremely acceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3
Acceptability of communication between yourself and the IC during the oral lead-in phase? · Neither acceptable nor unacceptable
|
1 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3
Acceptability of communication between yourself and the IC during the oral lead-in phase? · Somewhat unacceptable
|
1 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3
Acceptability of communication between yourself and the IC during the oral lead-in phase? · Very unacceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3
Acceptability of communication between yourself and the IC during the oral lead-in phase? · Extremely unacceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 3
Acceptability of communication between yourself and the IC during the oral lead-in phase? · I do not have knowledge of/not involved in this process
|
3 Participants
|
SECONDARY outcome
Timeframe: At Month 6Population: Analysis was performed on the Expert Panel which includes any Expert Panel member who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=6 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6
Acceptability of communication between yourself and the IC during the oral lead-in phase? · Very acceptable
|
1 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6
Acceptability of communication between yourself and the IC during the oral lead-in phase? · Somewhat acceptable
|
1 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6
Acceptability of insurance verification/confirmation process for patients referred to the IC · Extremely acceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6
Acceptability of insurance verification/confirmation process for patients referred to the IC · Very acceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6
Acceptability of insurance verification/confirmation process for patients referred to the IC · Somewhat acceptable
|
1 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6
Acceptability of insurance verification/confirmation process for patients referred to the IC · Neither acceptable nor unacceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6
Acceptability of insurance verification/confirmation process for patients referred to the IC · Somewhat unacceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6
Acceptability of insurance verification/confirmation process for patients referred to the IC · Very unacceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6
Acceptability of insurance verification/confirmation process for patients referred to the IC · Extremely unacceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6
Acceptability of insurance verification/confirmation process for patients referred to the IC · I do not have knowledge of/not involved in this process
|
1 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6
How acceptable has the process been for relaying insurance coverage information to patients? · Extremely acceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6
How acceptable has the process been for relaying insurance coverage information to patients? · Very acceptable
|
1 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6
How acceptable has the process been for relaying insurance coverage information to patients? · Somewhat acceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6
How acceptable has the process been for relaying insurance coverage information to patients? · Neither acceptable nor unacceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6
How acceptable has the process been for relaying insurance coverage information to patients? · Somewhat unacceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6
How acceptable has the process been for relaying insurance coverage information to patients? · Very unacceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6
How acceptable has the process been for relaying insurance coverage information to patients? · Extremely unacceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6
How acceptable has the process been for relaying insurance coverage information to patients? · I do not have knowledge of/not involved in this process
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6
Acceptability of communication between yourself and the IC during the oral lead-in phase? · Extremely acceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6
Acceptability of communication between yourself and the IC during the oral lead-in phase? · Neither acceptable nor unacceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6
Acceptability of communication between yourself and the IC during the oral lead-in phase? · Somewhat unacceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6
Acceptability of communication between yourself and the IC during the oral lead-in phase? · Very unacceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6
Acceptability of communication between yourself and the IC during the oral lead-in phase? · Extremely unacceptable
|
0 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of Insurance and Communication for CABENUVA Administration in Participants by Quantitative Questionnaires at Month 6
Acceptability of communication between yourself and the IC during the oral lead-in phase? · I do not have knowledge of/not involved in this process
|
4 Participants
|
SECONDARY outcome
Timeframe: Prior to Month 1 (Baseline)Population: Analysis was performed on the Expert Panel which includes any Expert Panel member who completed any portion of any questionnaire at the specified timepoint study.
The Expert Panel were asked about the key steps focused on the process of CABENUVA administration at IC/ASAs in order to inform the development of the blueprint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=8 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews Prior to Month 1
Staff Identify patients for CABENUVA and discuss with patient
|
2 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews Prior to Month 1
Staff formally refer patients to verify insurance
|
4 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews Prior to Month 1
Staff initiates patient on oral lead-in
|
3 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews Prior to Month 1
Staff schedules first patient visit and conducts pre-visit steps
|
2 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews Prior to Month 1
Patient attends first injection appointment
|
1 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews Prior to Month 1
Post injection reporting and future appointment scheduling
|
2 Participants
|
SECONDARY outcome
Timeframe: At Month 6Population: Analysis was performed on the Expert Panel which includes any Expert Panel member who completed any portion of any questionnaire at the specified timepoint study.
The Expert Panel were asked about the key steps focused on the process of CABENUVA administration at IC/ASAs in order to inform the development of the blueprint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=8 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews at Month 6
Staff Identify patients for CABENUVA and discuss with patient
|
2 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews at Month 6
Staff formally refer patients to verify insurance
|
3 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews at Month 6
Staff initiates patient on oral lead-in
|
2 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews at Month 6
Staff schedules first patient visit and conducts pre-visit steps
|
1 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews at Month 6
Patient attends first injection appointment
|
4 Participants
|
|
Number of Expert Panel Members Assessed for Feasibility, Acceptability and Process of CABENUVA Administration in Participants by Qualitative Interviews at Month 6
Post injection reporting and future appointment scheduling
|
5 Participants
|
SECONDARY outcome
Timeframe: At Month 1Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=44 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires at Month 1
Concern about unwanted disclosure of HIV status when attending appointments at HIV providers office · Very concerned
|
12 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires at Month 1
Concern about unwanted disclosure of HIV status when attending appointments at HIV providers office · Moderately concerned
|
7 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires at Month 1
Concern about unwanted disclosure of HIV status when attending appointments at HIV providers office · Somewhat concerned
|
4 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires at Month 1
Concern about unwanted disclosure of HIV status when attending appointments at HIV providers office · A little concerned
|
3 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires at Month 1
Concern about unwanted disclosure of HIV status when attending appointments at HIV providers office · Not at all concerned
|
17 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires at Month 1
Concern about unwanted disclosure of HIV status when attending appointments at HIV providers office · Missing
|
1 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires at Month 1
Concern about unwanted disclosure of HIV status when attending appointments at IC · Very concerned
|
10 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires at Month 1
Concern about unwanted disclosure of HIV status when attending appointments at IC · Moderately concerned
|
5 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires at Month 1
Concern about unwanted disclosure of HIV status when attending appointments at IC · Somewhat concerned
|
5 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires at Month 1
Concern about unwanted disclosure of HIV status when attending appointments at IC · A little concerned
|
5 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires at Month 1
Concern about unwanted disclosure of HIV status when attending appointments at IC · Not at all concerned
|
18 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires at Month 1
Concern about unwanted disclosure of HIV status when attending appointments at IC · Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: At Month 3 and 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=41 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 1) at Month 3 and 8
Month 3- Have you been treated differently, or experienced stigma or discrimination at the IC? · Yes
|
1 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 1) at Month 3 and 8
Month 3- Have you been treated differently, or experienced stigma or discrimination at the IC? · No
|
34 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 1) at Month 3 and 8
Month 3- Have you been treated differently, or experienced stigma or discrimination at the IC? · Prefer not to answer
|
1 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 1) at Month 3 and 8
Month 3- Have you been treated differently, or experienced stigma or discrimination at the IC? · Missing
|
5 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 1) at Month 3 and 8
Month 8- Have you been treated differently, or experienced stigma or discrimination at the IC? · Yes
|
1 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 1) at Month 3 and 8
Month 8- Have you been treated differently, or experienced stigma or discrimination at the IC? · No
|
34 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 1) at Month 3 and 8
Month 8- Have you been treated differently, or experienced stigma or discrimination at the IC? · Prefer not to answer
|
2 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 1) at Month 3 and 8
Month 8- Have you been treated differently, or experienced stigma or discrimination at the IC? · Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: At Months 3 and 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=1 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8
Month 3- Your experience at IC compared to your experience at your HIV provider's office/clinic? · A lot worse
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8
Month 3- Your experience at IC compared to your experience at your HIV provider's office/clinic? · Somewhat worse
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8
Month 3- Your experience at IC compared to your experience at your HIV provider's office/clinic? · A little worse
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8
Month 3- Your experience at IC compared to your experience at your HIV provider's office/clinic? · About the same
|
1 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8
Month 3- Your experience at IC compared to your experience at your HIV provider's office/clinic? · A little better
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8
Month 3- Your experience at IC compared to your experience at your HIV provider's office/clinic? · Somewhat better
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8
Month 3- Your experience at IC compared to your experience at your HIV provider's office/clinic? · A lot better
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8
Month 8- Your experience at IC compared to your experience at your HIV provider's office/clinic? · A lot worse
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8
Month 8- Your experience at IC compared to your experience at your HIV provider's office/clinic? · Somewhat worse
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8
Month 8- Your experience at IC compared to your experience at your HIV provider's office/clinic? · A little worse
|
1 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8
Month 8- Your experience at IC compared to your experience at your HIV provider's office/clinic? · About the same
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8
Month 8- Your experience at IC compared to your experience at your HIV provider's office/clinic? · A little better
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8
Month 8- Your experience at IC compared to your experience at your HIV provider's office/clinic? · Somewhat better
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 2) at Months 3 and 8
Month 8- Your experience at IC compared to your experience at your HIV provider's office/clinic? · A lot better
|
0 Participants
|
SECONDARY outcome
Timeframe: At Months 3 and 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=1 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8
Month 3- Do you believe you have been treated differently based on any of the following factors. · Age
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8
Month 3- Do you believe you have been treated differently based on any of the following factors. · Race/ethnicity
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8
Month 3- Do you believe you have been treated differently based on any of the following factors. · Sex
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8
Month 3- Do you believe you have been treated differently based on any of the following factors. · Gender identity
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8
Month 3- Do you believe you have been treated differently based on any of the following factors. · Sexual preference
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8
Month 3- Do you believe you have been treated differently based on any of the following factors. · HIV status
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8
Month 3- Do you believe you have been treated differently based on any of the following factors. · Religion
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8
Month 3- Do you believe you have been treated differently based on any of the following factors. · Physical appearance
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8
Month 3- Do you believe you have been treated differently based on any of the following factors. · Housing status
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8
Month 3- Do you believe you have been treated differently based on any of the following factors. · Due to pregnancy/being pregnant
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8
Month 3- Do you believe you have been treated differently based on any of the following factors. · Other
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8
Month 3- Do you believe you have been treated differently based on any of the following factors. · None of the above
|
1 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8
Month 8- Do you believe you have been treated differently based on any of the following factors. · Age
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8
Month 8- Do you believe you have been treated differently based on any of the following factors. · Race/ethnicity
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8
Month 8- Do you believe you have been treated differently based on any of the following factors. · Sex
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8
Month 8- Do you believe you have been treated differently based on any of the following factors. · Gender identity
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8
Month 8- Do you believe you have been treated differently based on any of the following factors. · Sexual preference
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8
Month 8- Do you believe you have been treated differently based on any of the following factors. · HIV status
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8
Month 8- Do you believe you have been treated differently based on any of the following factors. · Religion
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8
Month 8- Do you believe you have been treated differently based on any of the following factors. · Physical appearance
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8
Month 8- Do you believe you have been treated differently based on any of the following factors. · Housing status
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8
Month 8- Do you believe you have been treated differently based on any of the following factors. · Due to pregnancy/being pregnant
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8
Month 8- Do you believe you have been treated differently based on any of the following factors. · Other
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 3) at Months 3 and 8
Month 8- Do you believe you have been treated differently based on any of the following factors. · None of the above
|
1 Participants
|
SECONDARY outcome
Timeframe: At Months 3 and 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=41 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8
Month 3- How comfortable are you with the infusion center managing your CABENUVA injections? · Extremely comfortable
|
28 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8
Month 3- How comfortable are you with the infusion center managing your CABENUVA injections? · Very comfortable
|
6 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8
Month 3- How comfortable are you with the infusion center managing your CABENUVA injections? · Somewhat comfortable
|
2 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8
Month 3- How comfortable are you with the infusion center managing your CABENUVA injections? · Neutral
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8
Month 3- How comfortable are you with the infusion center managing your CABENUVA injections? · Somewhat uncomfortable
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8
Month 3- How comfortable are you with the infusion center managing your CABENUVA injections? · Very uncomfortable
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8
Month 3- How comfortable are you with the infusion center managing your CABENUVA injections? · Extremely uncomfortable
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8
Month 3- How comfortable are you with the infusion center managing your CABENUVA injections? · Missing
|
5 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8
Month 8- How comfortable are you with the infusion center managing your CABENUVA injections? · Extremely comfortable
|
24 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8
Month 8- How comfortable are you with the infusion center managing your CABENUVA injections? · Very comfortable
|
10 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8
Month 8- How comfortable are you with the infusion center managing your CABENUVA injections? · Somewhat comfortable
|
1 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8
Month 8- How comfortable are you with the infusion center managing your CABENUVA injections? · Neutral
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8
Month 8- How comfortable are you with the infusion center managing your CABENUVA injections? · Somewhat uncomfortable
|
1 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8
Month 8- How comfortable are you with the infusion center managing your CABENUVA injections? · Very uncomfortable
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8
Month 8- How comfortable are you with the infusion center managing your CABENUVA injections? · Extremely uncomfortable
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 4) at Months 3 and 8
Month 8- How comfortable are you with the infusion center managing your CABENUVA injections? · Missing
|
2 Participants
|
SECONDARY outcome
Timeframe: At Months 3 and 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=41 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8
Month 3- How welcome do you feel at the infusion center? · Extremely welcome
|
25 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8
Month 3- How welcome do you feel at the infusion center? · Very welcome
|
10 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8
Month 3- How welcome do you feel at the infusion center? · Somewhat welcome
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8
Month 3- How welcome do you feel at the infusion center? · Neutral
|
1 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8
Month 3- How welcome do you feel at the infusion center? · Somewhat unwelcome
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8
Month 3- How welcome do you feel at the infusion center? · Very unwelcome
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8
Month 3- How welcome do you feel at the infusion center? · Extremely unwelcome
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8
Month 3- How welcome do you feel at the infusion center? · Missing
|
5 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8
Month 8- How welcome do you feel at the infusion center? · Extremely welcome
|
29 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8
Month 8- How welcome do you feel at the infusion center? · Very welcome
|
7 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8
Month 8- How welcome do you feel at the infusion center? · Somewhat welcome
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8
Month 8- How welcome do you feel at the infusion center? · Neutral
|
1 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8
Month 8- How welcome do you feel at the infusion center? · Somewhat unwelcome
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8
Month 8- How welcome do you feel at the infusion center? · Very unwelcome
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8
Month 8- How welcome do you feel at the infusion center? · Extremely unwelcome
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 5) at Months 3 and 8
Month 8- How welcome do you feel at the infusion center? · Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: At Months 3 and 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=41 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8
Month 3- How respectful are the infusion center staff when you are there for your injections? · Extremely respectful
|
30 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8
Month 3- How respectful are the infusion center staff when you are there for your injections? · Very respectful
|
6 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8
Month 3- How respectful are the infusion center staff when you are there for your injections? · Somewhat respectful
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8
Month 3- How respectful are the infusion center staff when you are there for your injections? · Neutral
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8
Month 3- How respectful are the infusion center staff when you are there for your injections? · Somewhat unrespectful
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8
Month 3- How respectful are the infusion center staff when you are there for your injections? · Very unrespectful
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8
Month 3- How respectful are the infusion center staff when you are there for your injections? · Extremely unrespectful
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8
Month 3- How respectful are the infusion center staff when you are there for your injections? · Missing
|
5 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8
Month 8- How respectful are the infusion center staff when you are there for your injections? · Extremely respectful
|
31 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8
Month 8- How respectful are the infusion center staff when you are there for your injections? · Very respectful
|
6 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8
Month 8- How respectful are the infusion center staff when you are there for your injections? · Somewhat respectful
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8
Month 8- How respectful are the infusion center staff when you are there for your injections? · Neutral
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8
Month 8- How respectful are the infusion center staff when you are there for your injections? · Somewhat unrespectful
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8
Month 8- How respectful are the infusion center staff when you are there for your injections? · Very unrespectful
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8
Month 8- How respectful are the infusion center staff when you are there for your injections? · Extremely unrespectful
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 6) at Months 3 and 8
Month 8- How respectful are the infusion center staff when you are there for your injections? · Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: At Months 3 and 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=41 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8
Month 3- Satisfaction level of privacy at the IC for receiving your injections? · Extremely satisfied
|
25 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8
Month 3- Satisfaction level of privacy at the IC for receiving your injections? · Very satisfied
|
9 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8
Month 3- Satisfaction level of privacy at the IC for receiving your injections? · Somewhat satisfied
|
1 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8
Month 3- Satisfaction level of privacy at the IC for receiving your injections? · Neutral
|
1 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8
Month 3- Satisfaction level of privacy at the IC for receiving your injections? · Somewhat dissatisfied
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8
Month 3- Satisfaction level of privacy at the IC for receiving your injections? · Very dissatisfied
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8
Month 3- Satisfaction level of privacy at the IC for receiving your injections? · Extremely dissatisfied
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8
Month 3- Satisfaction level of privacy at the IC for receiving your injections? · Missing
|
5 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8
Month 8- Satisfaction level of privacy at the IC for receiving your injections? · Extremely satisfied
|
27 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8
Month 8- Satisfaction level of privacy at the IC for receiving your injections? · Very satisfied
|
6 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8
Month 8- Satisfaction level of privacy at the IC for receiving your injections? · Somewhat satisfied
|
1 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8
Month 8- Satisfaction level of privacy at the IC for receiving your injections? · Neutral
|
1 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8
Month 8- Satisfaction level of privacy at the IC for receiving your injections? · Somewhat dissatisfied
|
1 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8
Month 8- Satisfaction level of privacy at the IC for receiving your injections? · Very dissatisfied
|
1 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8
Month 8- Satisfaction level of privacy at the IC for receiving your injections? · Extremely dissatisfied
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 7) at Months 3 and 8
Month 8- Satisfaction level of privacy at the IC for receiving your injections? · Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: At Months 3 and 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=41 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8
Month 3- How convenient is it for you to get to the infusion center for your CABENUVA visits? · Very convenient
|
20 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8
Month 3- How convenient is it for you to get to the infusion center for your CABENUVA visits? · Somewhat convenient
|
7 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8
Month 3- How convenient is it for you to get to the infusion center for your CABENUVA visits? · A little convenient
|
3 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8
Month 3- How convenient is it for you to get to the infusion center for your CABENUVA visits? · Neutral
|
1 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8
Month 3- How convenient is it for you to get to the infusion center for your CABENUVA visits? · A little inconvenient
|
2 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8
Month 3- How convenient is it for you to get to the infusion center for your CABENUVA visits? · Somewhat inconvenient
|
3 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8
Month 3- How convenient is it for you to get to the infusion center for your CABENUVA visits? · Very inconvenient
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8
Month 3- How convenient is it for you to get to the infusion center for your CABENUVA visits? · Missing
|
5 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8
Month 8- How convenient is it for you to get to the infusion center for your CABENUVA visits? · Very convenient
|
23 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8
Month 8- How convenient is it for you to get to the infusion center for your CABENUVA visits? · Somewhat convenient
|
4 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8
Month 8- How convenient is it for you to get to the infusion center for your CABENUVA visits? · A little convenient
|
3 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8
Month 8- How convenient is it for you to get to the infusion center for your CABENUVA visits? · Neutral
|
3 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8
Month 8- How convenient is it for you to get to the infusion center for your CABENUVA visits? · A little inconvenient
|
2 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8
Month 8- How convenient is it for you to get to the infusion center for your CABENUVA visits? · Somewhat inconvenient
|
1 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8
Month 8- How convenient is it for you to get to the infusion center for your CABENUVA visits? · Very inconvenient
|
1 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 8) at Months 3 and 8
Month 8- How convenient is it for you to get to the infusion center for your CABENUVA visits? · Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: At Months 3 and 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=41 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 9) at Months 3 and 8
Month 3- How long does it typically take you to get to the infusion center? · 1-15 minutes
|
9 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 9) at Months 3 and 8
Month 3- How long does it typically take you to get to the infusion center? · 16-30 minutes
|
12 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 9) at Months 3 and 8
Month 3- How long does it typically take you to get to the infusion center? · 31-45 minutes
|
9 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 9) at Months 3 and 8
Month 3- How long does it typically take you to get to the infusion center? · 46-60 minutes
|
5 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 9) at Months 3 and 8
Month 3- How long does it typically take you to get to the infusion center? · More than 60 minutes
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 9) at Months 3 and 8
Month 3- How long does it typically take you to get to the infusion center? · Missing
|
6 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 9) at Months 3 and 8
Month 8- How long does it typically take you to get to the infusion center? · 1-15 minutes
|
8 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 9) at Months 3 and 8
Month 8- How long does it typically take you to get to the infusion center? · 16-30 minutes
|
15 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 9) at Months 3 and 8
Month 8- How long does it typically take you to get to the infusion center? · 31-45 minutes
|
11 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 9) at Months 3 and 8
Month 8- How long does it typically take you to get to the infusion center? · 46-60 minutes
|
1 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 9) at Months 3 and 8
Month 8- How long does it typically take you to get to the infusion center? · More than 60 minutes
|
2 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 9) at Months 3 and 8
Month 8- How long does it typically take you to get to the infusion center? · Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: At Months 3 and 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Participants were asked their opinion on who did they reach out to obtain answers to their questions.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=41 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8
Month 3- My regular HIV provider
|
18 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8
Month 3- Staff at infusion center
|
15 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8
Month 3- No questions to date
|
9 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8
Month 3- Other staff at my regular HIV provider's office
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8
Month 3- Other people with HIV
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8
Month 3- Social media
|
0 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8
Month 3- Missing
|
5 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8
Month 8- My regular HIV provider
|
20 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8
Month 8- Staff at the infusion center
|
18 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8
Month 8- No questions to date
|
11 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8
Month 8- Other staff at my regular HIV provider's office
|
2 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8
Month 8- Other people with HIV
|
1 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8
Month 8- Social media
|
1 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 10) at Months 3 and 8
Month 8- Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: At Months 3 and 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=41 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 11) at Months 3 and 8
Month 3- Concern about unwanted disclosure of HIV status when attending appointments at the IC? · Very concerned
|
2 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 11) at Months 3 and 8
Month 3- Concern about unwanted disclosure of HIV status when attending appointments at the IC? · Moderately concerned
|
5 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 11) at Months 3 and 8
Month 3- Concern about unwanted disclosure of HIV status when attending appointments at the IC? · Somewhat concerned
|
6 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 11) at Months 3 and 8
Month 3- Concern about unwanted disclosure of HIV status when attending appointments at the IC? · A little concerned
|
1 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 11) at Months 3 and 8
Month 3- Concern about unwanted disclosure of HIV status when attending appointments at the IC? · Not at all concerned
|
22 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 11) at Months 3 and 8
Month 3- Concern about unwanted disclosure of HIV status when attending appointments at the IC? · Missing
|
5 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 11) at Months 3 and 8
Month 8- Concern about unwanted disclosure of HIV status when attending appointments at the IC? · Very concerned
|
5 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 11) at Months 3 and 8
Month 8- Concern about unwanted disclosure of HIV status when attending appointments at the IC? · Moderately concerned
|
1 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 11) at Months 3 and 8
Month 8- Concern about unwanted disclosure of HIV status when attending appointments at the IC? · Somewhat concerned
|
4 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 11) at Months 3 and 8
Month 8- Concern about unwanted disclosure of HIV status when attending appointments at the IC? · A little concerned
|
5 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 11) at Months 3 and 8
Month 8- Concern about unwanted disclosure of HIV status when attending appointments at the IC? · Not at all concerned
|
22 Participants
|
|
Number of Participants Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration With Other Quantitative Questionnaires (Q 11) at Months 3 and 8
Month 8- Concern about unwanted disclosure of HIV status when attending appointments at the IC? · Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: Prior to Month 1 (Baseline)Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.
Since CABENUVA must be administered within a two-week treatment window every month, IC/ASA staff were asked their opinion about the ease or difficulty in appointment re-scheduling and implementation of CABENUVA administration in their work-flow.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=113 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1
How easy or difficult CABENUVA administration will be to implement in your current work-flow? · Extremely easy
|
9 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1
How easy or difficult CABENUVA administration will be to implement in your current work-flow? · Very easy
|
21 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1
How easy or difficult do you think the appointment re-scheduling will be? · Extremely easy
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1
How easy or difficult do you think the appointment re-scheduling will be? · Very easy
|
24 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1
How easy or difficult do you think the appointment re-scheduling will be? · Somewhat easy
|
16 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1
How easy or difficult do you think the appointment re-scheduling will be? · Neutral
|
46 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1
How easy or difficult do you think the appointment re-scheduling will be? · Somewhat difficult
|
15 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1
How easy or difficult do you think the appointment re-scheduling will be? · Very difficult
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1
How easy or difficult do you think the appointment re-scheduling will be? · Extremely difficult
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1
How easy or difficult CABENUVA administration will be to implement in your current work-flow? · Somewhat easy
|
21 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1
How easy or difficult CABENUVA administration will be to implement in your current work-flow? · Neutral
|
31 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1
How easy or difficult CABENUVA administration will be to implement in your current work-flow? · Somewhat difficult
|
19 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1
How easy or difficult CABENUVA administration will be to implement in your current work-flow? · Very difficult
|
9 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires Prior to Month 1
How easy or difficult CABENUVA administration will be to implement in your current work-flow? · Extremely difficult
|
3 Participants
|
SECONDARY outcome
Timeframe: At Month 3Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.
Since CABENUVA must be administered within a two-week treatment window (+/-)7 days relative to the target treatment date), the IC/ASA staff was asked their opinion about the ease or difficulty in appointment scheduling and re-scheduling and implementation of CABENUVA administration in their workflow.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=38 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in appointment scheduling for CABENUVA injections-Very easy
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in implementation of CABENUVA administration- Somewhat easy
|
3 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in implementation of CABENUVA administration- Neither easy nor difficult
|
16 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in implementation of CABENUVA administration- Very difficult
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in implementation of CABENUVA administration- Extremely difficult
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in implementation of CABENUVA administration- Missing
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in appointment scheduling for CABENUVA injections-Extremely easy
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in appointment scheduling for CABENUVA injections-Somewhat easy
|
7 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in appointment scheduling for CABENUVA injections-Neither easy nor difficult
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in appointment scheduling for CABENUVA injections-Somewhat difficult
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in appointment scheduling for CABENUVA injections-Very difficult
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in appointment scheduling for CABENUVA injections-Extremely difficult
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in appointment scheduling for CABENUVA injections-Unsure/not applicable to role
|
15 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in appointment scheduling for CABENUVA injections- Missing
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in appointment re-scheduling for CABENUVA injections- Extremely easy
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in appointment re-scheduling for CABENUVA injections- Very easy
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in appointment re-scheduling for CABENUVA injections- Somewhat easy
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in appointment re-scheduling for CABENUVA injections- Neither easy nor difficult
|
5 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in appointment re-scheduling for CABENUVA injections- Somewhat difficult
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in appointment re-scheduling for CABENUVA injections- Very difficult
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in appointment re-scheduling for CABENUVA injections- Extremely difficult
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in appointment re-scheduling for CABENUVA injections-Unsure/NA to role
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in appointment re-scheduling for CABENUVA injections- Missing
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in implementation of CABENUVA administration- Extremely easy
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in implementation of CABENUVA administration- Very easy
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in implementation of CABENUVA administration- Somewhat difficult
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 3
Ease or difficulty in implementation of CABENUVA administration- Unsure/not applicable to role
|
NA Participants
This category is not applicable for this question.
|
SECONDARY outcome
Timeframe: At Month 8Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.
Since CABENUVA must be administered within a two-week treatment window (+/-)7 days relative to the target treatment date), the IC/ASA staff was asked their opinion about the ease or difficulty in appointment scheduling and re-scheduling and implementation of CABENUVA administration in their workflow.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=26 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has CABENUVA administration been to implement in your current work-flow? · Missing
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has it been to schedule appointments for CABENUVA injections. · Extremely easy
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has it been to schedule appointments for CABENUVA injections. · Very easy
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has it been to schedule appointments for CABENUVA injections. · Somewhat easy
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has it been to schedule appointments for CABENUVA injections. · Neither easy nor difficult
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has it been to schedule appointments for CABENUVA injections. · Somewhat difficult
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has it been to schedule appointments for CABENUVA injections. · Very difficult
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has it been to schedule appointments for CABENUVA injections. · Extremely difficult
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has it been to schedule appointments for CABENUVA injections. · Unsure/not applicable to role
|
8 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has it been to schedule appointments for CABENUVA injections. · Missing
|
7 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has it been to reschedule appointments for CABENUVA injections? · Extremely easy
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has it been to reschedule appointments for CABENUVA injections? · Very easy
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has it been to reschedule appointments for CABENUVA injections? · Somewhat easy
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has it been to reschedule appointments for CABENUVA injections? · Neither easy nor difficult
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has it been to reschedule appointments for CABENUVA injections? · Somewhat difficult
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has it been to reschedule appointments for CABENUVA injections? · Very difficult
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has it been to reschedule appointments for CABENUVA injections? · Extremely difficult
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has it been to reschedule appointments for CABENUVA injections? · Unsure/not applicable to role
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has it been to reschedule appointments for CABENUVA injections? · Missing
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has CABENUVA administration been to implement in your current work-flow? · Extremely easy
|
3 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has CABENUVA administration been to implement in your current work-flow? · Very easy
|
3 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has CABENUVA administration been to implement in your current work-flow? · Somewhat easy
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has CABENUVA administration been to implement in your current work-flow? · Neither easy nor difficult
|
5 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has CABENUVA administration been to implement in your current work-flow? · Somewhat difficult
|
7 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has CABENUVA administration been to implement in your current work-flow? · Very difficult
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has CABENUVA administration been to implement in your current work-flow? · Extremely difficult
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Other Quantitative Questionnaires at Month 8
How easy or difficult has CABENUVA administration been to implement in your current work-flow? · Unsure/not applicable to role
|
NA Participants
This category is not applicable for this question.
|
SECONDARY outcome
Timeframe: At Month 1Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=3 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
Patients not being virologically suppressed due to missed injections · Extremely concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
Patients not being virologically suppressed due to missed injections · Moderately concerned
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
Patients not being virologically suppressed due to missed injections · Somewhat concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Somewhat concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Slightly concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Not at all concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Extremely concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Moderately concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Missing
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Extremely concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Moderately concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Somewhat concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Slightly concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Not at all concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Missing
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
Patients not being virologically suppressed due to missed injections · Slightly concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
Patients not being virologically suppressed due to missed injections · Not at all concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
Patients not being virologically suppressed due to missed injections · Missing
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
Being informed (in a timely manner) of adverse events · Extremely concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
Being informed (in a timely manner) of adverse events · Moderately concerned
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
Being informed (in a timely manner) of adverse events · Somewhat concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
Being informed (in a timely manner) of adverse events · Slightly concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
Being informed (in a timely manner) of adverse events · Not at all concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
Being informed (in a timely manner) of adverse events · Missing
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
IC's ability to manage other care needs of patients presenting to CABENUVA appointments · Extremely concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
IC's ability to manage other care needs of patients presenting to CABENUVA appointments · Moderately concerned
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
IC's ability to manage other care needs of patients presenting to CABENUVA appointments · Somewhat concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
IC's ability to manage other care needs of patients presenting to CABENUVA appointments · Slightly concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
IC's ability to manage other care needs of patients presenting to CABENUVA appointments · Not at all concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 1
IC's ability to manage other care needs of patients presenting to CABENUVA appointments · Missing
|
0 Participants
|
SECONDARY outcome
Timeframe: At Month 4Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=3 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Somewhat concerned
|
3 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Slightly concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
Patients not being virologically suppressed due to missed injections · Extremely concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
IC's ability to manage other care needs of patients presenting to CABENUVA appointments · Extremely concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
IC's ability to manage other care needs of patients presenting to CABENUVA appointments · Moderately concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
IC's ability to manage other care needs of patients presenting to CABENUVA appointments · Somewhat concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Extremely concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Moderately concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Not at all concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Missing
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Extremely concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Moderately concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Somewhat concerned
|
3 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Slightly concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Not at all concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Missing
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
Patients not being virologically suppressed due to missed injections · Moderately concerned
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
Patients not being virologically suppressed due to missed injections · Somewhat concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
Patients not being virologically suppressed due to missed injections · Slightly concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
Patients not being virologically suppressed due to missed injections · Not at all concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
Patients not being virologically suppressed due to missed injections · Missing
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
Being informed (in a timely manner) of adverse events · Extremely concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
Being informed (in a timely manner) of adverse events · Moderately concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
Being informed (in a timely manner) of adverse events · Somewhat concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
Being informed (in a timely manner) of adverse events · Slightly concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
Being informed (in a timely manner) of adverse events · Not at all concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
Being informed (in a timely manner) of adverse events · Missing
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
IC's ability to manage other care needs of patients presenting to CABENUVA appointments · Slightly concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
IC's ability to manage other care needs of patients presenting to CABENUVA appointments · Not at all concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 4
IC's ability to manage other care needs of patients presenting to CABENUVA appointments · Missing
|
0 Participants
|
SECONDARY outcome
Timeframe: At Month 8Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=3 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
IC's ability to manage other care needs of patients presenting to CABENUVA appointments · Extremely concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
IC's ability to manage other care needs of patients presenting to CABENUVA appointments · Moderately concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
IC's ability to manage other care needs of patients presenting to CABENUVA appointments · Slightly concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
IC's ability to manage other care needs of patients presenting to CABENUVA appointments · Not at all concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Extremely concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Moderately concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Somewhat concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Slightly concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Not at all concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
Being informed (in a timely manner) when a patient misses a CABENUVA visit · Missing
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Extremely concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Moderately concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Somewhat concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Slightly concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Not at all concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
Infusion Center's (lack of) persistence to follow up with patients on missed appointments · Missing
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
Patients not being virologically suppressed due to missed injections · Extremely concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
Patients not being virologically suppressed due to missed injections · Moderately concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
Patients not being virologically suppressed due to missed injections · Somewhat concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
Patients not being virologically suppressed due to missed injections · Slightly concerned
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
Patients not being virologically suppressed due to missed injections · Not at all concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
Patients not being virologically suppressed due to missed injections · Missing
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
Being informed (in a timely manner) of adverse events · Extremely concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
Being informed (in a timely manner) of adverse events · Moderately concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
Being informed (in a timely manner) of adverse events · Somewhat concerned
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
Being informed (in a timely manner) of adverse events · Slightly concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
Being informed (in a timely manner) of adverse events · Not at all concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
Being informed (in a timely manner) of adverse events · Missing
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
IC's ability to manage other care needs of patients presenting to CABENUVA appointments · Somewhat concerned
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants With Quantitative Questionnaires at Month 8
IC's ability to manage other care needs of patients presenting to CABENUVA appointments · Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: At Month 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Participants were asked about facilitators that made the process of receiving CABENUVA at IC/ASAs easier.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=28 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Facilitators of CABENUVA Administration by Qualitative Interviews at Month 8
IC/ASA staff make treatment a positive experience
|
8 Participants
|
|
Number of Participants Assessed for Facilitators of CABENUVA Administration by Qualitative Interviews at Month 8
Efficiency of treatment
|
3 Participants
|
|
Number of Participants Assessed for Facilitators of CABENUVA Administration by Qualitative Interviews at Month 8
Clear communication by IC/ASA staff
|
5 Participants
|
|
Number of Participants Assessed for Facilitators of CABENUVA Administration by Qualitative Interviews at Month 8
Convenience/accessibility of IC/ASA location
|
4 Participants
|
|
Number of Participants Assessed for Facilitators of CABENUVA Administration by Qualitative Interviews at Month 8
Ease of scheduling appointments and timely reminders
|
1 Participants
|
|
Number of Participants Assessed for Facilitators of CABENUVA Administration by Qualitative Interviews at Month 8
Not reported
|
7 Participants
|
SECONDARY outcome
Timeframe: At Month 8Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.
IC/ASA staff were asked their opinion on the infrastructure impact of administering CABENUVA.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=12 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of IC/ASA Staff Assessed for Barriers/Concerns of CABENUVA Administration in Participants by Qualitative Interviews at Month 8
Facilitates implementation
|
12 Participants
|
|
Number of IC/ASA Staff Assessed for Barriers/Concerns of CABENUVA Administration in Participants by Qualitative Interviews at Month 8
Scheduling system work arounds to accommodate visit window
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Barriers/Concerns of CABENUVA Administration in Participants by Qualitative Interviews at Month 8
Modifying visit duration to account for all the pieces of administering CABENUVA
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Barriers/Concerns of CABENUVA Administration in Participants by Qualitative Interviews at Month 8
Shortage of private rooms
|
4 Participants
|
SECONDARY outcome
Timeframe: At Month 8Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
HIV care providers were asked about the facilitators and challenges related to referring participants to IC/ASAs.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=3 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants by Qualitative Interviews at Month 8
Sending of prescription is not through EMR
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants by Qualitative Interviews at Month 8
Knowing which IC/ASAs offer CABENUVA
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants by Qualitative Interviews at Month 8
Multiple labs for participants
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants by Qualitative Interviews at Month 8
IC/ASA managing insurance
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants by Qualitative Interviews at Month 8
Participant self-motivation to manage care
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Perceptions, Facilitators and Barriers/Concerns of CABENUVA Administration in Participants by Qualitative Interviews at Month 8
IC/ASA staff support of process
|
1 Participants
|
SECONDARY outcome
Timeframe: At Month 1, 3 and 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=44 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8
Month 8- Where would you prefer to receive CABENUVA? · At an infusion center
|
21 Participants
|
|
Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8
Month 8- Where would you prefer to receive CABENUVA? · At home
|
10 Participants
|
|
Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8
Month 1- Where would you prefer to receive CABENUVA? · At an infusion center
|
28 Participants
|
|
Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8
Month 1- Where would you prefer to receive CABENUVA? · At home
|
8 Participants
|
|
Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8
Month 1- Where would you prefer to receive CABENUVA? · At my HIV doctor's clinic
|
5 Participants
|
|
Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8
Month 1- Where would you prefer to receive CABENUVA? · At a pharmacy
|
2 Participants
|
|
Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8
Month 1- Where would you prefer to receive CABENUVA? · Other
|
0 Participants
|
|
Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8
Month 1- Where would you prefer to receive CABENUVA? · Missing
|
1 Participants
|
|
Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8
Month 3- Where would you prefer to receive CABENUVA? · At an infusion center
|
18 Participants
|
|
Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8
Month 3- Where would you prefer to receive CABENUVA? · At home
|
9 Participants
|
|
Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8
Month 3- Where would you prefer to receive CABENUVA? · At my HIV doctor's clinic
|
6 Participants
|
|
Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8
Month 3- Where would you prefer to receive CABENUVA? · At a pharmacy
|
1 Participants
|
|
Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8
Month 3- Where would you prefer to receive CABENUVA? · Other
|
1 Participants
|
|
Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8
Month 3- Where would you prefer to receive CABENUVA? · Missing
|
6 Participants
|
|
Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8
Month 8- Where would you prefer to receive CABENUVA? · At my HIV doctor's clinic
|
3 Participants
|
|
Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8
Month 8- Where would you prefer to receive CABENUVA? · At a pharmacy
|
1 Participants
|
|
Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8
Month 8- Where would you prefer to receive CABENUVA? · Other
|
0 Participants
|
|
Number of Participants Assessed for Preference on the Location to Receive CABENUVA With Other Quantitative Questionnaires at Months 1, 3 and 8
Month 8- Where would you prefer to receive CABENUVA? · Missing
|
3 Participants
|
SECONDARY outcome
Timeframe: At Month 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=33 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Preference on the Location to Receive CABENUVA by Qualitative Interviews at Month 8
Comfortable with care at IC/ASA
|
20 Participants
|
|
Number of Participants Assessed for Preference on the Location to Receive CABENUVA by Qualitative Interviews at Month 8
Home
|
5 Participants
|
|
Number of Participants Assessed for Preference on the Location to Receive CABENUVA by Qualitative Interviews at Month 8
Closer proximity to participants
|
8 Participants
|
SECONDARY outcome
Timeframe: At Month 1Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
In this outcome measure, participants were asked about their views on the IC/ASA administration model (advantages of going to the infusion center to receive CABENUVA).
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=44 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1
Convenient location of the infusion center
|
22 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1
Ease of parking at the infusion center
|
21 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1
More privacy at the infusion center
|
19 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1
Convenient hours for the infusion center
|
17 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1
Reduced stigma
|
13 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1
I like that people do not know what medication I am there to receive
|
12 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1
Injections are not available at my provider's office
|
8 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1
Other
|
2 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1
No advantages of receiving CABENUVA at the infusion center
|
1 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1
Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: At Months 3 and 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
In this outcome measure, participants were asked about their views on the IC/ASA administration model (advantages of going to the infusion center to receive CABENUVA).
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=41 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Convenient location of the infusion center
|
20 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Ease of parking at the infusion center
|
19 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Ease of scheduling and rescheduling appointments
|
17 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- More privacy at the infusion center
|
17 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Convenient hours for the infusion center
|
13 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Reduced stigma
|
10 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- I like that people do not know what medication I am there to receive
|
12 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Injections are not available at my provider's office
|
11 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Other
|
0 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- No advantages of receiving CABENUVA at the infusion center
|
0 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Missing
|
5 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Convenient location of the infusion center
|
22 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Ease of parking at the infusion center
|
24 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Ease of scheduling and rescheduling appointments
|
21 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- More privacy at the infusion center
|
18 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Convenient hours for the infusion center
|
13 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Reduced stigma
|
16 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- I like that people do not know what medication I am there to receive
|
18 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Injections are not available at my provider's office
|
11 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Other
|
3 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- No advantages of receiving CABENUVA at the infusion center
|
2 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: At Months 1, 4 and 8Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
In this outcome measure, HIV care providers were asked about their views on the IC/ASA administration model (advantages of referring patients to an infusion center for CABENUVA).
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=3 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 1- Convenience for the patient
|
3 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 1- Infusions centers have more clinic space
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 1- Infusion centers have more time to add visits to their schedules
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 1- Infusion centers have more staff to manage scheduling or rescheduling appointments
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 1- Infusion centers have more staff to administer it
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 1- Infusion centers have the space to store the medication
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 1- Infusion center handles the logistics of administration
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 1- Infusion centers manage the insurance verification process
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 1- Infusion centers manage acquisition of the medication
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 1- Infusion centers manage the insurance reimbursement
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 1- Financial considerations for my clinic
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 1- Other
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 1- Missing
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 4- Convenience for the patient
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 4- Infusions centers have more clinic space
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 4- Infusion centers have more time to add visits to their schedules
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 4- Infusion centers have more staff to manage scheduling or rescheduling appointments
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 4- Infusion centers have more staff to administer it
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 4- Infusion centers have the space to store the medication
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 4- Infusion center handles the logistics of administration
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 4- Infusion centers manage the insurance verification process
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 4- Infusion centers manage acquisition of the medication
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 4- Infusion centers manage the insurance reimbursement
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 4- Financial considerations for my clinic
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 4- Other
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 4- Missing
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 8- Convenience for the patient
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 8- Infusions centers have more clinic space
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 8- Infusion centers have more time to add visits to their schedules
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 8- Infusion centers have more staff to manage scheduling or rescheduling appointments
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 8- Infusion centers have more staff to administer it
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 8- Infusion centers have the space to store the medication
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 8- Infusion center handles the logistics of administration
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 8- Infusion centers manage the insurance verification process
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 8- Infusion centers manage acquisition of the medication
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 8- Infusion centers manage the insurance reimbursement
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 8- Financial considerations for my clinic
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 8- Other
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1, 4 and 8
Month 8- Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: At Month 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=28 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8
Professionalism of staff
|
16 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8
Privacy
|
9 Participants
|
|
Number of Participants Assessed for Advantages of Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8
Overall convenience
|
14 Participants
|
SECONDARY outcome
Timeframe: At Month 8Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=2 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of HIV Care Providers Assessed for Advantages of Participants Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8
Convenience
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Advantages of Participants Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8
Efficiency
|
2 Participants
|
SECONDARY outcome
Timeframe: At Month 1Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
In this outcome measure, participants were asked about their views on the IC/ASA administration model (disadvantages of going to the infusion center to receive CABENUVA).
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=44 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1
Too many lab draws
|
0 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1
Infusion center doesn't know how to manage the pain or side effects of CABENUVA
|
0 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1
Missing
|
1 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1
No disadvantages of receiving CABENUVA at the infusion center
|
23 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1
Inconvenient location of the infusion center
|
8 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1
Unfamiliar with routine at the infusion center
|
5 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1
Inconvenient hours for the infusion center
|
4 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1
I don't want other people at the infusion center to know I have HIV
|
4 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1
Decreased contact with my HIV provider
|
3 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1
Too many appointments between the IC and the HIV doctors
|
3 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1
Unfamiliar with the infusion center staff
|
2 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1
Less privacy at the infusion center
|
2 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1
Other
|
1 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Month 1
Difficulty scheduling and rescheduling appointments at the infusion center
|
0 Participants
|
SECONDARY outcome
Timeframe: At Months 3 and 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
In this outcome measure, participants were asked about their views on the IC/ASA administration model (disadvantages of going to the infusion center to receive CABENUVA).
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=41 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Other
|
0 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- No disadvantages of receiving CABENUVA at the infusion center
|
16 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Inconvenient location of the infusion center
|
7 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Unfamiliar with routine at the infusion center
|
1 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Inconvenient hours for the infusion center
|
3 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- I don't want other people at the infusion center to know I have HIV
|
6 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Decreased contact with my HIV provider
|
7 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Too many appointments between the IC and the HIV doctors
|
2 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Unfamiliar with the infusion center staff
|
1 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Less privacy at the infusion center
|
2 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Difficulty scheduling and rescheduling appointments at the infusion center
|
0 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Too many lab draws
|
1 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Infusion center doesn't know how to manage the pain or side effects of CABENUVA
|
1 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- More stigma at the infusion center
|
2 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Difficulty of parking at the infusion center
|
0 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Missing
|
7 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- No disadvantages of receiving CABENUVA at the infusion center
|
17 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Inconvenient location of the infusion center
|
8 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Unfamiliar with routine at the infusion center
|
0 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Inconvenient hours for the infusion center
|
5 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- I don't want other people at the infusion center to know I have HIV
|
5 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Decreased contact with my HIV provider
|
7 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Too many appointments between the IC and the HIV doctors
|
1 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Unfamiliar with the infusion center staff
|
1 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Less privacy at the infusion center
|
3 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Other
|
1 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Difficulty scheduling and rescheduling appointments at the infusion center
|
0 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Too many lab draws
|
1 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Infusion center doesn't know how to manage the pain or side effects of CABENUVA
|
0 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- More stigma at the infusion center
|
1 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Difficulty of parking at the infusion center
|
2 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: At Month 1Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
In this outcome measure, HIV care providers were asked about their views on the IC/ASA administration model (potential disadvantages of referring patients to an IC for CABENUVA).
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=3 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1
Concern I won't be aware if my patient does not receive CABENUVA on time
|
3 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1
Concern about adverse event management
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1
Inconvenience for patients to go to two locations (clinic for routine visits and IC for injections)
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1
Concern about management of injection site reactions
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1
Concern patient won't want to go to infusion center
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1
Concern about stigma patient may experience receiving an CABENUVA at infusion center
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1
Missed opportunity for revenue for my HIV clinic
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1
Issues with ICs handling logistics associated with insurance verification and approval
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1
Concern I won't be aware when my patient receives CABENUVA
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1
Concern about reduced involvement in management of HIV-related care
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1
Issues with infusion centers handling the logistics associated with insurance reimbursement
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1
Fear of losing my patient to another provider
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1
Other
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Month 1
Missing
|
0 Participants
|
SECONDARY outcome
Timeframe: At Months 4 and 8Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
In this outcome measure, HIV care providers were asked about their views on the IC/ASA administration model (disadvantages of referring patients to an IC for CABENUVA).
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=3 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month 4- Concern about adverse event management
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month 4- Concern about management of injection site reactions
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month 4- Concern I won't be aware when my patient receives CABENUVA
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month 4- Concern about reduced involvement in management of HIV-related care
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month 4- Issues with infusion centers handling the logistics associated with insurance reimbursement
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month 4- Fear of losing my patient to another provider
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month 8- Concern about management of injection site reactions
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month 8- Concern patient won't want to go to infusion center
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month 8- Concern about stigma patient may experience receiving an CABENUVA at infusion center
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month 8- Missed opportunity for revenue for my HIV clinic
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month 8- Issues with infusion centers handling the logistics associated with insurance reimbursement
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month 8- Fear of losing my patient to another provider
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month 8- Other
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month 8- Missing
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month 4- Concern I won't be aware if my patient does not receive CABENUVA on time
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month4-Inconvenience for patients to go to 2 locations(clinic for routine visits & IC for injections
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month 4- Concern patient won't want to go to infusion center
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month 4- Concern about stigma patient may experience receiving an CABENUVA at infusion center
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month 4- Missed opportunity for revenue for my HIV clinic
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month 4- Issues with ICs handling logistics associated with insurance verification and approval
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month 4- Other
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month 4- Missing
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month 8- Concern I won't be aware if my patient does not receive CABENUVA on time
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month 8- Concern about adverse event management
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month8-Inconvenience for patients to go to 2 locations(clinic for routine visits & IC for injections
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month 8- Issues with ICs handling logistics associated with insurance verification and approval
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month 8- Concern I won't be aware when my patient receives CABENUVA
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages of Referring Participants to the IC/ ASA to Receive CABENUVA by Other Quantitative Questionnaires at Months 4 and 8
Month 8- Concern about reduced involvement in management of HIV-related care
|
2 Participants
|
SECONDARY outcome
Timeframe: At Month 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=28 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8
Distance spent traveling to IC/ASA
|
17 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8
Not reported
|
8 Participants
|
|
Number of Participants Assessed for Disadvantages of Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8
Privacy due to traveling outside home for treatment
|
3 Participants
|
SECONDARY outcome
Timeframe: At Month 8Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
In this outcome measure, HIV care providers were asked about their views on the IC/ASA administration model (disadvantages for participants receiving CABENUVA at IC/ASAs).
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=2 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of HIV Care Providers Assessed for Disadvantages for Participants Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8
Stigma
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Disadvantages for Participants Receiving CABENUVA at IC/ ASA by Qualitative Interviews at Month 8
Does not see how it is easier for participants
|
1 Participants
|
SECONDARY outcome
Timeframe: At Month 1Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=44 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1
How acceptable is it to you to come to the infusion center for CABENUVA? · Very acceptable
|
34 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1
How acceptable is it to you to come to the infusion center for CABENUVA? · Somewhat acceptable
|
6 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1
How acceptable is it to you to come to the infusion center for CABENUVA? · A little acceptable
|
0 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1
How acceptable is it to you to come to the infusion center for CABENUVA? · Neutral
|
2 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1
How acceptable is it to you to come to the infusion center for CABENUVA? · A little unacceptable
|
0 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1
How acceptable is it to you to come to the infusion center for CABENUVA? · Somewhat unacceptable
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1
How acceptable is it to you to come to the infusion center for CABENUVA? · Very unacceptable
|
0 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1
How acceptable is it to you to come to the infusion center for CABENUVA? · Missing
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1
Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)? · Very acceptable
|
19 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1
Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)? · Somewhat acceptable
|
11 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1
Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)? · A little acceptable
|
0 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1
Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)? · Neutral
|
6 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1
Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)? · A little unacceptable
|
4 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1
Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)? · Somewhat unacceptable
|
2 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1
Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)? · Very unacceptable
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1
Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)? · Missing
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1
How acceptable is it for you to get labs drawn at the infusion center? · Very acceptable
|
32 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1
How acceptable is it for you to get labs drawn at the infusion center? · Somewhat acceptable
|
5 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1
How acceptable is it for you to get labs drawn at the infusion center? · A little acceptable
|
0 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1
How acceptable is it for you to get labs drawn at the infusion center? · Neutral
|
5 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1
How acceptable is it for you to get labs drawn at the infusion center? · A little unacceptable
|
0 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1
How acceptable is it for you to get labs drawn at the infusion center? · Somewhat unacceptable
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1
How acceptable is it for you to get labs drawn at the infusion center? · Very unacceptable
|
0 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 1
How acceptable is it for you to get labs drawn at the infusion center? · Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: At Month 3Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=41 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3
How acceptable is it for you to get labs drawn at the infusion center? · Somewhat unacceptable
|
0 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3
How acceptable is it for you to get labs drawn at the infusion center? · Very unacceptable
|
3 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3
How acceptable is it for you to get labs drawn at the infusion center? · Missing
|
5 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3
How acceptable is it to you to come to the infusion center for CABENUVA? · Very acceptable
|
24 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3
How acceptable is it to you to come to the infusion center for CABENUVA? · Somewhat acceptable
|
9 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3
How acceptable is it to you to come to the infusion center for CABENUVA? · A little acceptable
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3
How acceptable is it to you to come to the infusion center for CABENUVA? · Neutral
|
0 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3
How acceptable is it to you to come to the infusion center for CABENUVA? · A little unacceptable
|
0 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3
How acceptable is it to you to come to the infusion center for CABENUVA? · Somewhat unacceptable
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3
How acceptable is it to you to come to the infusion center for CABENUVA? · Very unacceptable
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3
How acceptable is it to you to come to the infusion center for CABENUVA? · Missing
|
5 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3
Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)? · Very acceptable
|
14 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3
Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)? · Somewhat acceptable
|
7 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3
Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)? · A little acceptable
|
6 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3
Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)? · Neutral
|
3 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3
Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)? · A little unacceptable
|
2 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3
Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)? · Somewhat unacceptable
|
2 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3
Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)? · Very unacceptable
|
2 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3
Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)? · Missing
|
5 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3
How acceptable is it for you to get labs drawn at the infusion center? · Very acceptable
|
27 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3
How acceptable is it for you to get labs drawn at the infusion center? · Somewhat acceptable
|
3 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3
How acceptable is it for you to get labs drawn at the infusion center? · A little acceptable
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3
How acceptable is it for you to get labs drawn at the infusion center? · Neutral
|
2 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 3
How acceptable is it for you to get labs drawn at the infusion center? · A little unacceptable
|
0 Participants
|
SECONDARY outcome
Timeframe: At Month 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=38 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8
How acceptable is it to you to come to the infusion center for CABENUVA? · Very acceptable
|
23 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8
How acceptable is it to you to come to the infusion center for CABENUVA? · Somewhat acceptable
|
8 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8
How acceptable is it to you to come to the infusion center for CABENUVA? · A little acceptable
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8
How acceptable is it to you to come to the infusion center for CABENUVA? · Neutral
|
4 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8
How acceptable is it to you to come to the infusion center for CABENUVA? · A little unacceptable
|
0 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8
How acceptable is it to you to come to the infusion center for CABENUVA? · Somewhat unacceptable
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8
How acceptable is it to you to come to the infusion center for CABENUVA? · Very unacceptable
|
0 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8
How acceptable is it to you to come to the infusion center for CABENUVA? · Missing
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8
Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)? · Very acceptable
|
15 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8
Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)? · Somewhat acceptable
|
9 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8
Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)? · A little acceptable
|
4 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8
Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)? · Neutral
|
4 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8
Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)? · A little unacceptable
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8
Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)? · Somewhat unacceptable
|
2 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8
Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)? · Very unacceptable
|
2 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8
Acceptability to go to separate places for care (IC for CABENUVA and clinic for HIV appointments)? · Missing
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8
How acceptable is it for you to get labs drawn at the infusion center? · Very acceptable
|
33 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8
How acceptable is it for you to get labs drawn at the infusion center? · Somewhat acceptable
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8
How acceptable is it for you to get labs drawn at the infusion center? · A little acceptable
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8
How acceptable is it for you to get labs drawn at the infusion center? · Neutral
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8
How acceptable is it for you to get labs drawn at the infusion center? · A little unacceptable
|
0 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8
How acceptable is it for you to get labs drawn at the infusion center? · Somewhat unacceptable
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8
How acceptable is it for you to get labs drawn at the infusion center? · Very unacceptable
|
0 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Other Quantitative Questionnaires at Month 8
How acceptable is it for you to get labs drawn at the infusion center? · Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: At Months 3 and 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=41 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs (Time Spent at IC) by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Not including first visit, how much time have you spent at the IC for your CABENUVA visits? · 46-60 minutes
|
2 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs (Time Spent at IC) by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Not including first visit, how much time have you spent at the IC for your CABENUVA visits? · More than 60 minutes
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs (Time Spent at IC) by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Not including first visit, how much time have you spent at the IC for your CABENUVA visits? · Missing
|
5 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs (Time Spent at IC) by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Not including first visit, how much time have you spent at the IC for your CABENUVA visits? · 1-15 minutes
|
4 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs (Time Spent at IC) by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Not including first visit, how much time have you spent at the IC for your CABENUVA visits? · 16-30 minutes
|
10 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs (Time Spent at IC) by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Not including first visit, how much time have you spent at the IC for your CABENUVA visits? · 31-45 minutes
|
12 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs (Time Spent at IC) by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Not including first visit, how much time have you spent at the IC for your CABENUVA visits? · 46-60 minutes
|
10 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs (Time Spent at IC) by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Not including first visit, how much time have you spent at the IC for your CABENUVA visits? · More than 60 minutes
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs (Time Spent at IC) by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Not including first visit, how much time have you spent at the IC for your CABENUVA visits? · 1-15 minutes
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs (Time Spent at IC) by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Not including first visit, how much time have you spent at the IC for your CABENUVA visits? · 16-30 minutes
|
17 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs (Time Spent at IC) by Other Quantitative Questionnaires at Months 3 and 8
Month 3- Not including first visit, how much time have you spent at the IC for your CABENUVA visits? · 31-45 minutes
|
15 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs (Time Spent at IC) by Other Quantitative Questionnaires at Months 3 and 8
Month 8- Not including first visit, how much time have you spent at the IC for your CABENUVA visits? · Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: At Months 1, 4 and 8Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
HIV care providers were asked about the type of patients they found acceptable to refer to an IC to receive CABENUVA.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=3 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
All patients, Month 8
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Patients who want to start CABENUVA but prefer not to come to HIV clinic for each injection, Month 1
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Patients who want to start CABENUVA but prefer not to come to HIV clinic for each injection, Month 4
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Patients who want to start CABENUVA but prefer not to come to HIV clinic for each injection, Month 8
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Older patients (>50 years old), Month 8
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Missing, Month 1
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
All patients, Month 1
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
All patients, Month 4
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Patients who have had difficulty maintaining their daily oral treatment regimen, Month 1
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Patients who have had difficulty maintaining their daily oral treatment regimen, Month 4
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Patients who have had difficulty maintaining their daily oral treatment regimen, Month 8
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Patients already receiving CABENUVA, Month 1
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Patients already receiving CABENUVA, Month 4
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Patients already receiving CABENUVA, Month 8
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Other, Month 1
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Other, Month 4
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Other, Month 8
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Patients who have concerns about disclosure of their HIV status to others, Month 1
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Patients who have concerns about disclosure of their HIV status to others, Month 4
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Patients who have concerns about disclosure of their HIV status to others, Month 8
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Patients who feel stigmatized by their HIV, Month 1
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Patients who feel stigmatized by their HIV, Month 4
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Patients who feel stigmatized by their HIV, Month 8
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Patients with more chaotic lifestyles (variable work schedules, frequent travel etc), Month 1
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Patients with more chaotic lifestyles (variable work schedules, frequent travel etc), Month 4
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Patients with more chaotic lifestyles (variable work schedules, frequent travel etc), Month 8
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Patients with more structured lifestyles, Month 1
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Patients with more structured lifestyles, Month 4
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Patients with more structured lifestyles, Month 8
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Newly diagnosed (<2 years since diagnosis), Month 1
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Newly diagnosed (<2 years since diagnosis), Month 4
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Newly diagnosed (<2 years since diagnosis), Month 8
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Treatment experienced, Month 1
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Treatment experienced, Month 4
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Treatment experienced, Month 8
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Younger patients (<35 years old), Month 1
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Younger patients (<35 years old), Month 4
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Younger patients (<35 years old), Month 8
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Older patients (>50 years old), Month 1
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Older patients (>50 years old), Month 4
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Missing, Month 4
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Referring Participants to the IC/ ASA for CABENUVA by Other Quantitative Questionnaires at Months 1, 4 and 8
Missing, Month 8
|
1 Participants
|
SECONDARY outcome
Timeframe: At Month 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Participants were asked about their opinion on the acceptability of CABENUVA administration at the IC.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=28 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Qualitative Interviews at Month 8
Good facilities/environment
|
8 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Qualitative Interviews at Month 8
Professional and caring staff
|
23 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Qualitative Interviews at Month 8
Consistency of providers
|
2 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Qualitative Interviews at Month 8
Protects participants' privacy
|
14 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Qualitative Interviews at Month 8
Scheduling flexibility
|
4 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Qualitative Interviews at Month 8
Appointment reminders
|
1 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Qualitative Interviews at Month 8
Quick and easy administration process
|
6 Participants
|
|
Number of Participants Assessed for Acceptability of the Process of Receiving Injections at ICs/ ASAs by Qualitative Interviews at Month 8
Hassle-free for participants
|
1 Participants
|
SECONDARY outcome
Timeframe: At Month 8Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=2 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Participants Receiving Injections at ICs/ ASAs by Qualitative Interviews at Month 8
Reinforcing to have it as an option
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Acceptability of the Process of Participants Receiving Injections at ICs/ ASAs by Qualitative Interviews at Month 8
Not reported
|
1 Participants
|
SECONDARY outcome
Timeframe: Prior to Month 1 (Baseline)Population: Analysis was planned to be performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint. Prior to Month 1 there were no referrals given; hence the blueprint was not used and therefore it was not assessed.
The blueprint guides IC/ASA staff on what to do with referrals to receive CABENUVA at the IC/ASA.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: At Months 3 and 8Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.
The blueprint guides IC/ASA staff on what to do with referrals to receive CABENUVA at the IC/ASA.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=20 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires at Month 3 and 8
At month 3 - How useful is the blueprint? · Extremely useful
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires at Month 3 and 8
At month 3 - How useful is the blueprint? · Very useful
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires at Month 3 and 8
At month 3 - How useful is the blueprint? · Somewhat useful
|
7 Participants
|
|
Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires at Month 3 and 8
At month 3 - How useful is the blueprint? · Neutral
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires at Month 3 and 8
At month 3 - How useful is the blueprint? · Not very useful
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires at Month 3 and 8
At month 3 - How useful is the blueprint? · Not useful at all
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires at Month 3 and 8
At month 8 - How useful is the blueprint? · Extremely useful
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires at Month 3 and 8
At month 8 - How useful is the blueprint? · Very useful
|
3 Participants
|
|
Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires at Month 3 and 8
At month 8 - How useful is the blueprint? · Somewhat useful
|
5 Participants
|
|
Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires at Month 3 and 8
At month 8 - How useful is the blueprint? · Neutral
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires at Month 3 and 8
At month 8 - How useful is the blueprint? · Not very useful
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention With Other Quantitative Questionnaires at Month 3 and 8
At month 8 - How useful is the blueprint? · Not useful at all
|
1 Participants
|
SECONDARY outcome
Timeframe: At Months 4 and 8Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=2 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8
Month 4- Information in the POT is comprehensive enough for IC to administer CABENUVA to patients · Strongly Agree
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8
Month 4- Information in the POT is comprehensive enough for IC to administer CABENUVA to patients · Agree
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8
Month 4- Information in the POT is comprehensive enough for IC to administer CABENUVA to patients · Occasionally
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8
Month 4- Information in the POT is comprehensive enough for IC to administer CABENUVA to patients · Neither agree nor disagree
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8
Month 4- Information in the POT is comprehensive enough for IC to administer CABENUVA to patients · Disagree
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8
Month 4- Information in the POT is comprehensive enough for IC to administer CABENUVA to patients · Strongly disagree
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8
Month 4- The POT has all information it should have for the infusion center to administer CABENUVA · Strongly Agree
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8
Month 4- The POT has all information it should have for the infusion center to administer CABENUVA · Agree
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8
Month 4- The POT has all information it should have for the infusion center to administer CABENUVA · Occasionally
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8
Month 4- The POT has all information it should have for the infusion center to administer CABENUVA · Neither agree nor disagree
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8
Month 4- The POT has all information it should have for the infusion center to administer CABENUVA · Disagree
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8
Month 4- The POT has all information it should have for the infusion center to administer CABENUVA · Strongly disagree
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8
Month 8- Information in the POT is comprehensive enough for IC to administer CABENUVA to patients · Strongly Agree
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8
Month 8- Information in the POT is comprehensive enough for IC to administer CABENUVA to patients · Agree
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8
Month 8- Information in the POT is comprehensive enough for IC to administer CABENUVA to patients · Occasionally
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8
Month 8- Information in the POT is comprehensive enough for IC to administer CABENUVA to patients · Neither agree nor disagree
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8
Month 8- Information in the POT is comprehensive enough for IC to administer CABENUVA to patients · Disagree
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8
Month 8- Information in the POT is comprehensive enough for IC to administer CABENUVA to patients · Strongly disagree
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8
Month 8- The POT has all information it should have for the infusion center to administer CABENUVA · Strongly Agree
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8
Month 8- The POT has all information it should have for the infusion center to administer CABENUVA · Agree
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8
Month 8- The POT has all information it should have for the infusion center to administer CABENUVA · Occasionally
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8
Month 8- The POT has all information it should have for the infusion center to administer CABENUVA · Neither agree nor disagree
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8
Month 8- The POT has all information it should have for the infusion center to administer CABENUVA · Disagree
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Usefulness of Plan of Treatment (POT) by Other Quantitative Questionnaires at Months 4 and 8
Month 8- The POT has all information it should have for the infusion center to administer CABENUVA · Strongly disagree
|
0 Participants
|
SECONDARY outcome
Timeframe: Month 8Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=12 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention and POT Assessed by Qualitative Interviews at Month 8
Usefulness of the blueprint - Usage
|
2 Participants
|
|
Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention and POT Assessed by Qualitative Interviews at Month 8
Usefulness of the blueprint - Familiarity
|
3 Participants
|
|
Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention and POT Assessed by Qualitative Interviews at Month 8
Usefulness of the blueprint- Not reported
|
7 Participants
|
|
Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention and POT Assessed by Qualitative Interviews at Month 8
Usefulness of POT - Usage
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Usefulness of the Blueprint Intervention and POT Assessed by Qualitative Interviews at Month 8
Usefulness of POT- Not reported
|
11 Participants
|
SECONDARY outcome
Timeframe: Month 8Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
The blueprint guides HIV care providers on what to do with referrals to receive CABENUVA at the IC/ASA.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=2 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of HIV Care Providers Assessed for Usefulness of the Blueprint Intervention and POT by Qualitative Interviews at Month 8
Usefulness of blueprint · Sufficient in providing information to the IC/ASA
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Usefulness of the Blueprint Intervention and POT by Qualitative Interviews at Month 8
Usefulness of blueprint · Not reported
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Usefulness of the Blueprint Intervention and POT by Qualitative Interviews at Month 8
Usefulness of POT · Sufficient in providing information to the IC/ASA
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Usefulness of the Blueprint Intervention and POT by Qualitative Interviews at Month 8
Usefulness of POT · Not reported
|
1 Participants
|
SECONDARY outcome
Timeframe: Prior to Month 1 (Baseline) and Months 3 and 8Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=113 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8
Baseline- Overall opinion about administering CABENUVA for participants at your infusion center? · Extremely positive
|
14 Participants
|
|
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8
Baseline- Overall opinion about administering CABENUVA for participants at your infusion center? · Very positive
|
21 Participants
|
|
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8
Baseline- Overall opinion about administering CABENUVA for participants at your infusion center? · Somewhat positive
|
21 Participants
|
|
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8
Baseline- Overall opinion about administering CABENUVA for participants at your infusion center? · Neutral
|
37 Participants
|
|
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8
Baseline- Overall opinion about administering CABENUVA for participants at your infusion center? · Somewhat negative
|
15 Participants
|
|
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8
Baseline- Overall opinion about administering CABENUVA for participants at your infusion center? · Very negative
|
3 Participants
|
|
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8
Baseline- Overall opinion about administering CABENUVA for participants at your infusion center? · Extremely negative
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8
Month 8- Overall opinion about administering CABENUVA for participants at your infusion center? · Extremely positive
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8
Month 8- Overall opinion about administering CABENUVA for participants at your infusion center? · Very positive
|
3 Participants
|
|
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8
Month 8- Overall opinion about administering CABENUVA for participants at your infusion center? · Somewhat positive
|
5 Participants
|
|
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8
Month 8- Overall opinion about administering CABENUVA for participants at your infusion center? · Neutral
|
7 Participants
|
|
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8
Month 8- Overall opinion about administering CABENUVA for participants at your infusion center? · Somewhat negative
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8
Baseline- Overall opinion about administering CABENUVA for participants at your infusion center? · Missing
|
1 Participants
|
|
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8
Month 3- Overall opinion about administering CABENUVA for participants at your infusion center? · Extremely positive
|
3 Participants
|
|
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8
Month 3- Overall opinion about administering CABENUVA for participants at your infusion center? · Very positive
|
6 Participants
|
|
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8
Month 3- Overall opinion about administering CABENUVA for participants at your infusion center? · Somewhat positive
|
3 Participants
|
|
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8
Month 3- Overall opinion about administering CABENUVA for participants at your infusion center? · Neutral
|
17 Participants
|
|
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8
Month 3- Overall opinion about administering CABENUVA for participants at your infusion center? · Somewhat negative
|
5 Participants
|
|
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8
Month 3- Overall opinion about administering CABENUVA for participants at your infusion center? · Very negative
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8
Month 3- Overall opinion about administering CABENUVA for participants at your infusion center? · Extremely negative
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8
Month 3- Overall opinion about administering CABENUVA for participants at your infusion center? · Missing
|
4 Participants
|
|
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8
Month 8- Overall opinion about administering CABENUVA for participants at your infusion center? · Very negative
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8
Month 8- Overall opinion about administering CABENUVA for participants at your infusion center? · Extremely negative
|
0 Participants
|
|
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Other Quantitative Questionnaires Prior to Month 1 and at Months 3 and 8
Month 8- Overall opinion about administering CABENUVA for participants at your infusion center? · Missing
|
7 Participants
|
SECONDARY outcome
Timeframe: At Months 1, 3 and 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=44 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8
At month 8 - What is your overall opinion about going to an infusion center to receive CABENUVA? · Neutral
|
0 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8
At month 1 - What is your overall opinion about going to an infusion center to receive CABENUVA? · Very positive
|
35 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8
At month 1 - What is your overall opinion about going to an infusion center to receive CABENUVA? · Somewhat positive
|
5 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8
At month 1 - What is your overall opinion about going to an infusion center to receive CABENUVA? · A little positive
|
1 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8
At month 1 - What is your overall opinion about going to an infusion center to receive CABENUVA? · Neutral
|
1 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8
At month 1 - What is your overall opinion about going to an infusion center to receive CABENUVA? · A little negative
|
1 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8
At month 1 - What is your overall opinion about going to an infusion center to receive CABENUVA? · Somewhat negative
|
0 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8
At month 1 - What is your overall opinion about going to an infusion center to receive CABENUVA? · Very negative
|
0 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8
At month 1 - What is your overall opinion about going to an infusion center to receive CABENUVA? · Missing
|
1 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8
At month 3 - What is your overall opinion about going to an infusion center to receive CABENUVA? · Very positive
|
28 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8
At month 3 - What is your overall opinion about going to an infusion center to receive CABENUVA? · Somewhat positive
|
7 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8
At month 3 - What is your overall opinion about going to an infusion center to receive CABENUVA? · A little positive
|
1 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8
At month 3 - What is your overall opinion about going to an infusion center to receive CABENUVA? · Neutral
|
0 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8
At month 3 - What is your overall opinion about going to an infusion center to receive CABENUVA? · A little negative
|
0 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8
At month 3 - What is your overall opinion about going to an infusion center to receive CABENUVA? · Somewhat negative
|
0 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8
At month 3 - What is your overall opinion about going to an infusion center to receive CABENUVA? · Very negative
|
0 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8
At month 3 - What is your overall opinion about going to an infusion center to receive CABENUVA? · Missing
|
5 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8
At month 8 - What is your overall opinion about going to an infusion center to receive CABENUVA? · Very positive
|
27 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8
At month 8 - What is your overall opinion about going to an infusion center to receive CABENUVA? · Somewhat positive
|
9 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8
At month 8 - What is your overall opinion about going to an infusion center to receive CABENUVA? · A little positive
|
0 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8
At month 8 - What is your overall opinion about going to an infusion center to receive CABENUVA? · A little negative
|
1 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8
At month 8 - What is your overall opinion about going to an infusion center to receive CABENUVA? · Somewhat negative
|
0 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8
At month 8 - What is your overall opinion about going to an infusion center to receive CABENUVA? · Very negative
|
0 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Other Quantitative Questionnaires at Months 1, 3 and 8
At month 8 - What is your overall opinion about going to an infusion center to receive CABENUVA? · Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: At Month 1Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=3 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 1
Always
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 1
Often
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 1
Occasionally
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 1
Rarely
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 1
Never
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 1
Missing
|
0 Participants
|
SECONDARY outcome
Timeframe: At Month 4Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=3 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 4
Very acceptable
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 4
Somewhat acceptable
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 4
A little acceptable
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 4
Neutral
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 4
A little unacceptable
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 4
Somewhat unacceptable
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 4
Very unacceptable
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 4
I have not interacted with the infusion center yet.
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 4
Missing
|
0 Participants
|
SECONDARY outcome
Timeframe: At Month 8Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=3 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 8
Somewhat dissatisfied
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 8
Very dissatisfied
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 8
Extremely dissatisfied
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 8
Extremely satisfied
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 8
Very satisfied
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 8
Somewhat satisfied
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 8
Neutral
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 8
I was not involved in this process
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring the Participant to an IC/ ASA by Other Quantitative Questionnaires at Month 8
Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: At Month 8Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=3 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of HIV Care Providers Assessed for Overall Opinion of Continuing to Refer Participants to an IC/ ASA by Other Quantitative Questionnaires at Month 8
Extremely likely
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Continuing to Refer Participants to an IC/ ASA by Other Quantitative Questionnaires at Month 8
Very likely
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Continuing to Refer Participants to an IC/ ASA by Other Quantitative Questionnaires at Month 8
Somewhat likely
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Continuing to Refer Participants to an IC/ ASA by Other Quantitative Questionnaires at Month 8
Neutral
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Continuing to Refer Participants to an IC/ ASA by Other Quantitative Questionnaires at Month 8
Somewhat unlikely
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Continuing to Refer Participants to an IC/ ASA by Other Quantitative Questionnaires at Month 8
Very unlikely
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Continuing to Refer Participants to an IC/ ASA by Other Quantitative Questionnaires at Month 8
Extremely unlikely
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Continuing to Refer Participants to an IC/ ASA by Other Quantitative Questionnaires at Month 8
I was not involved in this process
|
0 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Continuing to Refer Participants to an IC/ ASA by Other Quantitative Questionnaires at Month 8
Missing
|
1 Participants
|
SECONDARY outcome
Timeframe: At Month 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
Participants were asked about their overall favorable and non-favorable opinion of receiving CABENUVA at the IC/ASA.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=28 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Qualitative Interview at Month 8
Treatment cadence
|
13 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Qualitative Interview at Month 8
Not needing to worry about forgetting to take the pill
|
5 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Qualitative Interview at Month 8
Reduced worry about unwanted disclosure of HIV
|
4 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Qualitative Interview at Month 8
Reduces pill burden
|
6 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Qualitative Interview at Month 8
No more pill side effects
|
2 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Qualitative Interview at Month 8
Effectiveness of treatment
|
5 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Qualitative Interview at Month 8
Convenience of treatment
|
11 Participants
|
|
Number of Participants Assessed for Overall Opinion of Receiving the Injection at an IC/ ASA by Qualitative Interview at Month 8
No daily reminder of diagnosis
|
5 Participants
|
SECONDARY outcome
Timeframe: At Month 8Population: Analysis was performed on the HIV care providers which includes any HIV care provider who completed any portion of any questionnaire at the specified timepoint.
HIV care providers were asked about their overall favoring and non-favoring opinions on referring participants to IC/ASA for CABENUVA administration.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=2 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring Patients to an IC/ ASA by Qualitative Interview at Month 8
Painful for participants
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring Patients to an IC/ ASA by Qualitative Interview at Month 8
Alternative treatment option for participants
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring Patients to an IC/ ASA by Qualitative Interview at Month 8
Advantages of CABENUVA over daily pill regimen
|
2 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring Patients to an IC/ ASA by Qualitative Interview at Month 8
Lack of effectiveness
|
1 Participants
|
|
Number of HIV Care Providers Assessed for Overall Opinion of Referring Patients to an IC/ ASA by Qualitative Interview at Month 8
Injection location on participant
|
1 Participants
|
SECONDARY outcome
Timeframe: At Month 8Population: Analysis was performed on the IC/ASA staff which includes any IC/ASA staff who completed any portion of any questionnaire at the specified timepoint.
IC/ASA staff was asked about their overall opinion on the participants referral process.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=12 Participants
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Qualitative Interview at Month 8
Clinical staff not involved
|
12 Participants
|
|
Number of IC/ASA Staff Assessed for Overall Opinion of Administering the Injection at an IC/ ASA by Qualitative Interview at Month 8
Field questions from participants regarding referring friends
|
1 Participants
|
SECONDARY outcome
Timeframe: Up to and including Month 8Population: Analysis was performed on the Safety set which includes any participant who completed any portion of any questionnaire at the specified timepoint.
This outcome measure evaluates the fidelity to treatment and dosing window. Fidelity to treatment and dosing window was defined based on a ±7-day window from target treatment date based on the calendar date of baseline injection.
Outcome measures
| Measure |
Participants Receiving CABENUVA
n=195 Injections
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
Number of Injections Occurring Within Target Window From Target Date
<-14 days
|
0 Injections
|
|
Number of Injections Occurring Within Target Window From Target Date
-14 to -8 days
|
3 Injections
|
|
Number of Injections Occurring Within Target Window From Target Date
-7 to -4 days
|
37 Injections
|
|
Number of Injections Occurring Within Target Window From Target Date
-3 to -2 days
|
27 Injections
|
|
Number of Injections Occurring Within Target Window From Target Date
-1 day
|
9 Injections
|
|
Number of Injections Occurring Within Target Window From Target Date
0 day
|
36 Injections
|
|
Number of Injections Occurring Within Target Window From Target Date
1 day
|
16 Injections
|
|
Number of Injections Occurring Within Target Window From Target Date
2 to 3 days
|
24 Injections
|
|
Number of Injections Occurring Within Target Window From Target Date
4 to 7 days
|
38 Injections
|
|
Number of Injections Occurring Within Target Window From Target Date
8 to 14 days
|
3 Injections
|
|
Number of Injections Occurring Within Target Window From Target Date
>14 days
|
1 Injections
|
|
Number of Injections Occurring Within Target Window From Target Date
Missed injection
|
1 Injections
|
Adverse Events
Participants Receiving CABENUVA
Serious events: 0 serious events
Other events: 13 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Participants Receiving CABENUVA
n=44 participants at risk
Eligible participants received CABENUVA injections intramuscularly at infusion centers/ASAs monthly or every-2-months.
|
|---|---|
|
General disorders
Injection site discomfort
|
13.6%
6/44 • Number of events 8 • Serious adverse events (SAEs) and other adverse events (AEs) were reported from Month 1 (signing of informed consent) to Month 8 (study completion).
SAEs, solicited AEs and unsolicited AEs were reported for the Safety set.
|
|
General disorders
Injection site pain
|
13.6%
6/44 • Number of events 7 • Serious adverse events (SAEs) and other adverse events (AEs) were reported from Month 1 (signing of informed consent) to Month 8 (study completion).
SAEs, solicited AEs and unsolicited AEs were reported for the Safety set.
|
|
General disorders
Fatigue
|
2.3%
1/44 • Number of events 2 • Serious adverse events (SAEs) and other adverse events (AEs) were reported from Month 1 (signing of informed consent) to Month 8 (study completion).
SAEs, solicited AEs and unsolicited AEs were reported for the Safety set.
|
|
General disorders
Injection site nodule
|
2.3%
1/44 • Number of events 1 • Serious adverse events (SAEs) and other adverse events (AEs) were reported from Month 1 (signing of informed consent) to Month 8 (study completion).
SAEs, solicited AEs and unsolicited AEs were reported for the Safety set.
|
|
Nervous system disorders
Presyncope
|
2.3%
1/44 • Number of events 1 • Serious adverse events (SAEs) and other adverse events (AEs) were reported from Month 1 (signing of informed consent) to Month 8 (study completion).
SAEs, solicited AEs and unsolicited AEs were reported for the Safety set.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.
- Publication restrictions are in place
Restriction type: OTHER